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Isocarbacyclin is a valuable synthetic target that has been recognized as a 
potential neuroprotective agent against ischemic stroke. Herein we describe a step-
economical synthesis of isocarbacyclin in an enantioselective fashion. The synthetic route 
utilizes a palladium-catalyzed decarboxylative coupling of a pentadienyl dienoate, a 
rhodium-catalyzed diene-diene [2+2+1] cycloaddition, and a ruthenium-catalyzed cross-
metathesis reaction. The metathesis reaction is particularly valuable since it allows for 
late-stage diversification; as a result other analogues were synthesized from the same 
building block. Another new synthetic route will be described that was designed to use 
the same combination of metal-catalyzed reactions for the synthesis of a tricyclic 
isocarbacyclin analogue. Instead of completing the tricyclic analogue, a novel cyclization 
was discovered. 
During the course of our synthesis of isocarbacyclin analogues, we discovered a 
decarboxylation reaction of a pentadienyl dienoate that did not require an anion 
stabilizing group. This novel decarboxylative coupling reaction, optimization, 
mechanistic evaluation, and substrate scope will also be described in detail.  
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CHAPTER I 
INTRODUCTION 
1. Background and Significance 
The last century has experienced development of synthetic strategies and 
syntheses of medicinal leads.
1
 The total synthesis of synthetic or natural molecules 
exhibit almost infinite variations as they present puzzles that require scientists to solve 
challenges in their structures for which solutions are not available from known synthetic 
methods.
1
 One of the challenges in total synthesis for many targets is the number of steps, 
which influences time, cost and amount of waste and byproducts.
2
 It is for that reason, 
Wender et al. focus on the step economy in total synthesis to simplify complex 
therapeutic leads syntheses.
3–6
 There are three approaches to achieve step-economical 
synthesis.
3,5,7
 The first approach is to have a larger increase in target-relevant complexity 
per a step by developing new reactions. The second approach is based on targeting the 
function, not the structure, of medicinal agents and simplifying the target complexity 
which is a strategy of function-oriented synthesis.
3,6
 The third approach is to achieve a 
late-stage diversification where subsequent analogues of the medicinal target could be 
synthesized from the same building block. 
Isocarbacyclin (1.2), a synthetic analogue of prostacyclin, is one of the medicinal 
targets that was first synthesized in the 1980’s (Figure 1.1).8 Isocarbacyclin (1.2) has 
shown neuroprotective activity after ischemic stroke
9
, however, studying its biological 
2 
 
activity was limited as a result of its syntheses with 15-20 steps by different research 
groups.
8,10–15
  
 
Figure 1.1. Prostacyclin (1.1) and Isocarbacyclin (1.2) Structures. 
Herein, we present an enantioselective step-economical synthesis of 
isocarbacyclin (1.2) in only 9 steps utilizing inexpensive and commercially available 
starting materials (Scheme 1.1).
7,16
 For this synthetic route we developed two new 
reactions: a decarboxylation of pentadienyl dienoate systems and [2+2+1] cycloaddition 
of bis-diene systems.
16
  
 
Scheme 1.1. Step-Economical Synthesis of Isocarbacyclin and Its Bicyclic Analogues. 
These two new reactions led to a rapid increase in the molecular complexity to 
afford the bicyclic core of isocarbacyclin (1.2) with four stereocenters as desired. 
Moreover a late-stage cross metathesis reaction enabled us to synthesize other analogues 
3 
 
of isocarbacyclin by using other simplified alkenes and from the same building block 
which further shorten the synthesis to 7 or 8 steps (Figure 1.2). 
 
Figure 1.2. Utilization of Step-Saving Techniques in the Synthesis of Isocarbacyclin and 
Simplified Analogues. 
Despite the increase in the molecular complexity in the cycloaddition reaction, the 
yield for this step was low, which led us to develop a new synthetic route where we 
modified the starting bis-diene compound for the cycloaddition reaction. Moreover the 
structure of the final tricyclic analogue (1.3) was designed to position the α-side chain in 
a manner similar to prostacyclin (1.1, Figure 1.3). 
4 
 
 
Figure 1.3. Tricyclic Analogue (1.4) Structurally Is More Related to Prostacyclin (1.1). 
A model system for the tricyclic analogues was prepared to test the two new 
reactions, decarboxylation and [2+2+1] cycloaddition. Having the novel reactions worked 
successfully a total synthesis was designed for the tricyclic analogues of isocarbacyclin. 
The total synthesis was designed in a way to use the same combination of the three metal-
catalyzed reactions that were used previously in the synthesis of bicyclic analogues 
(Scheme 1.2). 
 
Scheme 1.2. Step-Economical Synthesis of Tricyclic Isocarbacyclin Analogues. 
 The new decarboxylation reaction that was utilized for the synthesis of 
isocarbacyclin analogues is also described in greater detail. Metal-catalyzed cross-
coupling reactions have had a great impact on the synthesis of biologically active 
synthetic and natural compounds.
17
 Prominent among these reactions are the palladium-
5 
 
catalyzed carbon-carbon bond-forming reactions.
17
 One such reaction is decarboxylative 
coupling that utilizes a metal to generate organometallic intermediates that are coupled at 
the end (Figure 1.4). 
 
Figure 1.4. Decarboxylative Coupling. 
A major limitation in the current decarboxylation reactions is that harsh 
conditions and an anion-stabilizing group are often required.
18–20
 A decarboxylative 
coupling reaction was designed by Croatt research group of a dienoic acid (1.4) and bis-
allylic (1.5) pentadienyl (1.6) substrates at ambient temperature without the need of 
anion-stabilizing group (Scheme 1.3). This reaction was also found to be successful for 
both intramolecular and intermolecular cases. 
 
Scheme 1.3. Novel Decarboxylative Coupling of Dienoic Acids (1.4) and Bis-Allylic  
(1.5) or Pentadienyl (1.6) Substrates. 
6 
 
The novel decarboxylation was optimized for its catalyst, additives, solvent and 
temperature. Different reactions and conditions were screened to investigate the 
mechanism of this reaction with computational studies to propose two mechanisms. 
Having the conditions optimized, different substrates with substitutions on every unique 
position of both coupling substrates was examined. Substrates screened afforded either 
the desired product 1,3,6,8-tetraene (1.7) or the undesired rearranged ester (1.8, Scheme 
1.3). 
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CHAPTER II 
STEP-ECONOMICAL SYNTHESIS OF CLINPROST AND ANALOGUES  
UTILIZING A NOVEL DECARBOXYLATION REACTION 
Abu Deiab, G. I.; Croatt, M. P. In Strategies and Tactics in Organic Synthesis;  
Harmata, M., Ed.; Academic Press, 2017; Vol. 12, pp. 95-117. 
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Abstract: We present our step-economical synthesis of clinprost, the methyl ester 
of isocarbacyclin, and analogues. Isocarbacyclin is a valuable target due to its 
neuroprotection from the oxidative damage after a stroke. Specifically, we utilized a 
palladium-catalyzed decarboxylative coupling of a pentadienyl dienoate, a rhodium-
catalyzed diene-diene [2+2+1] cycloaddition, and a ruthenium-catalyzed cross-metathesis 
reaction. The decarboxylation reaction is the first decarboxylation of its type since the 
carboxyl-bearing carbon does not possess an anion-stabilizing group. In this chapter, we 
present some of our research into this novel reaction. The diene-diene [2+2+1] 
cycloaddition is the first cyclocarbonylation between two dienes. The metathesis reaction 
is particularly valuable since it allows for late-stage diversification. These three metal-
catalyzed reactions enabled us to complete the synthesis of clinprost in nine steps, seven 
for some analogues, instead of the 15 or more steps that have been previously reported. 
Keywords: Isocarbacyclin, clinprost, stroke, neuroprotection, step-economy, new 
reactions, decarboxylation, diene, pentadienyl dienoate, bicycle, metathesis,  
cycloaddition, palladium, rhodium, ruthenium 
1. Introduction and Background 
1.1 Step Economy in Organic Synthesis 
During the early stages of synthetic organic chemistry, the major efforts were to 
determine if the synthesis of certain compounds was possible. There were many 
incredible accomplishments1 including the syntheses of morphine,2 strychnine,3,4 
quinine5,6 and taxol.7–12 While continuing research efforts in this first area, later research 
11 
 
added in the aspect of learning to make compounds more selectively. Efforts with 
regioselectivity, diastereoselectivity, and enantioselectivity were all studied and resulted 
in many tremendous discoveries including reactions dealing with the Diels-Alder 
cycloaddition,13 the aldol reaction,14 and various oxidations15 and reductions.16 In more 
recent years, research has centered on making compounds in a more practical manner. 
With this last focus, significant efforts have focused on items relating to step,17 atom,18 
and redox19,20 economies. All of these economies tie in with efforts to approach the ideal 
synthesis, which is a synthesis that occurs in one step from readily available starting 
materials and in 100% yield, and includes facile product isolation and no waste 
generation.21  
In order to approach the ideal synthesis, efforts in our group have focused 
primarily on the step economy aspect. This is because the number of steps of a synthesis 
has a strong correlation with many of the important aspects of the ideal synthesis. There 
are essentially three ways to shorten the number of steps of a synthesis, which relates to 
the molecular complexity of the target (Figure 2.1, top graph). These options are to have 
a steeper slope for the complexity increase per step (left graph), decrease the complexity 
of the target (center graph), or use a more complex starting material (right graph). 
Importantly, all three of these approaches can be used together to synergistically shorten 
the number of steps in a synthesis (bottom graph). 
12 
 
 
Figure 2.1. Strategies to Improve Step Economy in Organic Synthesis. 
The left graph of Figure 2.1 requires the design and development of new reactions 
that have a more rapid increase in target-relevant molecular complexity.22 Two examples 
of this approach being used in synthesis are Reppe and Toepel’s synthesis of 
cyclooctatetraene23 and Wender’s synthesis of silphinene.24 The first synthesis of 
cyclooctatetraene by Willstätter and Wasser was highly significant, however, it required 
13 steps from a complex starting material with a 2% overall yield.25 Twenty-nine years 
later Reppe and Toepel were able to perform a cyclotetramerization of acetylene to 
13 
 
generate large quantities of cyclooctatetraene.23 Wender’s synthesis of silphinene utilized 
an arene-alkene meta-photocycloaddition to introduce significant target-relevant 
molecular complexity and synthesize the target in only three steps from simple starting 
materials instead of 10-21 steps, as has been reported by others.22,26 
The center graph (Figure 2.1) appears to be overly simplifying the process since it 
is changing the target complexity, but this is a strategy of function-oriented synthesis.10 
Instead of only targeting a structure, the goal is to target the function of a structure and 
simplify it while retaining or improving on the function. This is what often occurs in 
pharmaceutical companies when modifying a complex natural product to develop an 
active pharmaceutical ingredient. A recent example is the development of fingolimod as a 
drug for multiple sclerosis by chemical modification of a natural product myriocin.27,28 
Myriocin was isolated from a fungus and had three stereocenters and would have been 
moderately difficult to synthesize. Optimization of the structure decreased the complexity 
and removed all stereocenters to obtain a more easily synthesized structure while 
maintaining activity. 
The right graph (Figure 2.1) can represent two different opportunities to 
synthesize compounds. First, this could represent semisynthesis, which is how Taxol® is 
currently being produced.29 Taxol® and its derivatives were not only game-changers for 
the treatment of cancer but have been, and continue to be, blockbuster drugs.30 De novo 
synthesis of Taxol® was not practical to access sufficient quantities,7–12 but a related 
structure, 10-deacetylbaccatin III, can be used to start with more molecular complexity.7 
The other approach that is represented by the right graph is late-stage diversification. 
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Although late-stage diversification does not increase the molecular complexity of the 
starting material, it accesses an intermediate with higher complexity. Thus, subsequent 
analogues do not need to start from the complexity of the starting material but from the 
complexity of the branching point. This decreases the total number of steps for the 
synthesis of analogues. 
The bottom graph represents what happens when all three of these step-shortening 
techniques are used together. As illustrated by that graph, there can be even more 
significant step-savings when two or more approaches are used. In the synthetic route 
presented in this chapter, all three approaches were combined through the use of new 
reactions. This led to a rapid increase the molecular complexity, a function-oriented 
synthesis to decrease the molecular complexity of the target, and a late-stage  
diversification to decrease the total number of steps for analogues. 
1.2 Prostacyclin and Its Activity 
Prostacyclin (2.1), an endogenous bicyclic prostaglandin (PGI2), was structurally 
characterized in 1976 by the research group of John Vane, a biochemist in the United 
Kingdom (Figure 2.2).31 It is biologically synthesized from arachidonic acid and 
commonly prescribed under the name of Flolan® (epoprostenol) for patients with primary 
pulmonary hypertension.32,33 Prostacyclin (2.1) is a highly potent vasodilator and 
inhibitor of platelet aggregation; however, it is unstable due to the labile nature of the 
vinyl ether in the bicyclic ring system.31,34 Having a half-life of minutes in vitro, 
prostacyclin use in clinical applications is limited. This fact led to the development of 
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new analogues with the aim of generating chemical stability while maintaining or 
improving the physiological activity.35 The first generation of analogues simply replaced 
the ethereal oxygen with a methylene group with no other changes in structure.36 This 
analogue, known as carbacyclin (2.2; Figure 2.2), was indeed more stable, but showed 
significant side effects, such as headache and severe facial flushing during clinical 
trials.37  
 
Figure 2.2. Prostacyclin and its Analogues. 
The second generation of synthetic analogues isomerized an alkene, which led to 
the development of clinprost (2.3; Figure 2.2) and its active metabolite isocarbacyclin 
(2.4), both of which were found to be more stable than prostacyclin (2.1).38–41 In addition 
to vasodilation, isocarbacyclin and its methyl ester, clinprost, were found to have 
neuroprotective activity in animal models following ischemic stroke. Isocarbacyclin 
possesses a bicyclo[3.3.0]octene system with four stereocenters and a sidechain 
connected to the exocyclic alkene, which is called the ω-sidechain, and another α-
sidechain that contains the carboxylic acid moiety. The Rα and Rω nomenclature derives 
from the α and ω parts of arachidonic acid, which is the biosynthetic precursor for 
prostacyclin (2.1). 
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Importantly, the only treatment currently approved for ischemic stroke includes 
anticoagulant medicines like warfarin and antiplatelet medicines like aspirin and Plavix® 
(clopidogrel).42 These are only effective in treating vasoconstriction and blood clot 
dissolution by restoring blood flow to the affected area of the brain and preventing 
recurrent ischemic stroke for patients. Thus, the need for additional potential treatments 
that protect against neuronal damage in the brain following ischemic attack is urgent and 
increasing. As research continued, the third generation of isocarbacyclin analogues 
(Figure 2.3) was reported in 1996, including 15S-TIC (2.5; 15S-16-m-tolyl-17,18,19,20-
tetranorisocarbacyclin), 15R-TIC (2.6) and 15-deoxy TIC (2.7).43,44 These analogues were 
synthesized to test the necessity of the alcohol functional group in the ω-sidechain as well 
as the role of stereochemistry in that position. It was found that removing the alcohol 
functionality or reversing its stereochemical configuration completely diminished the 
vasodilation effect and only protection against neuronal death remained.45 
 
Figure 2.3. Isocarbacyclin Analogues for Testing the Necessity of the Alcohol Functional  
Group. 
As previously stated, the vasodilating capabilities of prostacyclin (2.1) have been 
known for decades and it was shown to be helpful for patients with pulmonary 
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hypertension. It was also hypothesized to be helpful to patients with ischemic stroke.46 
There are two types of stroke, hemorrhagic and ischemic. Hemorrhagic strokes occur 
when blood vessels in the brain are weak and burst to cause bleeding. Ischemic strokes, 
which accounts for about 87% of reported strokes,47 are caused by blood clots in the brain 
that lead to reduced blood flow and, as a result, reduced availability of oxygen and 
glucose in the affected area.48 This reduction in blood flow is followed by rapid influx of 
reactive oxygen species, a process known as reperfusion, after circulation of blood is 
restored. Both the initial low oxygen and glucose levels and the subsequent reperfusion 
cause extensive damage to the neurons.49 Isocarbacyclin (2.4) and its analogues were 
found to show a protective effect against neuronal damage following ischemic stroke in 
animal models.38–41 Different synthetic methods for isocarbacyclin and its analogues have 
been reported by several groups; however, most are more than 20 steps with the shortest 
being 15 steps from commercially available starting materials.43,44,50–55 Synthetic 
challenges, including the construction of the bicyclic ring system, regioselectivity of both 
the endocyclic double bond (C6-C9α), and the α-sidechain, are some of the reasons for 
the long syntheses.43,44 Moreover, there is the problem of how to selectively introduce the 
four stereocenters and the variability in regard to the ω-sidechain. The total synthesis of 
isocarbacyclin methyl ester, clinprost (2.3), was published by our research group in 
2013.56 Three late-stage steps in the synthesis use different transition metal-catalyzed 
reactions to rapidly assemble the target. The introduction of complexity and 
chemoselectivity resulted in an enantioselective synthesis of clinprost (2.3) that is nine 
total steps from commercially available starting materials. 
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In most of the prior syntheses, optically active starting materials were used to 
synthesize isocarbacyclin (2.4) and different analogues.43,44,50–55 Many of these synthetic 
routes involve either annulation of a five-membered ring onto an optically active 
cyclopentane derivative (2.8 – 2.11; Figure 2.4) that is commercially available or using a 
staring material that already has a bicyclo[3.3.0]octane skeleton (2.12 and 2.13; Figure 
2.4). An issue that limited these approaches is how to selectively introduce the endocyclic 
double bond.  
 
Figure 2.4. Optically Active Starting Materials Used Previously for Different  
Isocarbacyclin Syntheses. 
In 2005, Neil Sheddan and Johann Mulzer reported a new route for the synthesis 
of 15S-TIC (2.5), 15R-TIC (2.6) and 15-deoxy TIC (2.7) that takes advantage of two key 
reactions: the regioselective generation of the endocyclic double bond with an sp2-sp3 
palladium-catalyzed cross-coupling reaction (C5-C6) to install the α-sidechain and the 
generation of the exocyclic double bond by Julia-Kocienski olefination to install the ω-
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sidechain at a late stage in the synthesis (Figure 2.5).57 However, this approach still 
required 20 steps. One year later the same group reported another synthesis for the same 
analogues in which the ω-sidechain was installed by a cross metathesis reaction (Figure 
2.5).58 While this approach allows for diversity of Rω, the synthesis still needed four 
subsequent steps to access each analogue after the metathesis reaction. 
 
Figure 2.5. Sheddan and Mulzer’s Synthetic Approaches to Isocarbacyclin Analogues. 
2. Retrosynthetic Analysis 
The synthetic routes that have been reported for isocarbacyclin (2.4) and its 
analogues require at least 15 steps and most allow for very little diversification of the key 
ω-sidechain. While examining the functionality produced by a rhodium-catalyzed diene-
ene [2+2+1] cycloaddition, which has been previously reported by Mitchell Croatt and 
Paul Wender58 (Figure 2.6), it was noted that alkenyl cyclopentanone core system 2.16 
resulting from this reaction is similar to the isocarbacyclin bicyclic core system. This 
cycloaddition involves a diene-ene reactant, which, when treated with 10 mol % of a 
rhodium(I) catalyst under carbon monoxide atmosphere, smoothly converts to the 
[2+2+1] product with the formation of three stereocenters that have the same relative 
stereochemical configuration as the isocarbacyclin bicyclic core. It was envisioned that 
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reduction of the ketone would selectively occur from the convex face of the bicycle to 
generate the correct carbinol stereochemistry. 
 
Figure 2.6. Diene-ene [2+2+1] Cycloaddition and Comparison with Isocarbacyclin. 
Based on the 2006 report by Sheddan and Mulzer using cross metathesis to 
synthesize isocarbacyclin analogues (Figure 2.7), it was envisioned that the remaining 
olefin from the [2+2+1] cycloaddition could be attached to the Rω sidechain.
57 
Furthermore, different alkenes could be installed to get different ω-sidechains from a 
single compound at a late-stage in the synthesis. Due to the availability of alkenes and the 
target-relevant complexity of the bicyclic core, this approach could have a high level of 
step economy.  
 
Figure 2.7. Cross Metathesis for the Synthesis of Isocarbacyclin Analogues. 
With these results in mind, we were attracted to two key points. The first was that 
building the complex bicyclic core system (2.20), with the four stereocenters as desired, 
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could be achieved by diene-ene [2+2+1] cycloaddition of bis-diene (2.21) followed by 
reduction. The second attractive point was the diversification that could be achieved by 
cross metathesis at a late stage to get different analogues from the same bicyclic core 
(2.20). As a result, a retrosynthesis was conceived (Scheme 2.1) of isocarbacyclin methyl 
ester, or clinprost (2.3), having only nine steps.56 The first part of the synthesis, and most 
difficult part, was to generate bis-diene (2.21). 
 
Scheme 2.1. Retrosynthesis for Clinprost and Analogues 
3. Synthesis of the Bis-Diene Building Block 
3.1 Ortho-ester Approaches 
Our first generation attempt to synthesize isocarbacyclin analogues utilized ortho 
esters with the Rα-sidechain so that simple hydrolysis would generate the final analogues 
after assembling the bicyclic core (2.22; Scheme 2.2). It was envisioned that the bis-diene 
(2.23) could be formed by double dehydration of diol 2.24. Diol 2.24 could be formed by 
a reaction of two vinyl-Griniard reagents with a dialdehyde resulting from ozonolysis of 
cyclopentene 2.25. 
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Scheme 2.2. Retrosynthesis of Ortho Ester 2.22. 
The first ortho ester was derived from cyclohexanetriol (Scheme 2.3). The 
conversion of nitrile 2.26 to the cyclohexyl ortho ester (2.28) first traversed trimethyl 
ortho-ester 2.27.59 After multiple attempts to form and utilize cyclohexyl ortho ester 2.28, 
it was determined that hydrolysis to the ester (2.29) was sufficiently problematic. 
Hydrolysis could be dealt with if needed, but instead it was decided to use an alternative 
ortho ester protecting group. 
 
Scheme 2.3. Preparation of Ortho Ester from Cyclohexanetriol. 
The second ortho ester examined was derived from oxetane 2.31 (Scheme 2.4). 
Formation of this ortho ester (2.32) proceeded much better and it was much more 
stable.60 Unfortunately, attempts at subsequent coupling reactions, by formation of the 
cuprate, were not successful with either cyclopentenyl chloride or cyclopentene oxide. 
Although both of these electrophiles are highly reactive, alternative intramolecular 
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reactions were possible, in addition to hydrolysis of the ortho ester or decomposition of 
the electrophiles.  
 
Scheme 2.4. Attempted Application of Ortho Ester 2.32. 
At this stage in the project, we decided to use a model system to try and learn 
more about the potential of future steps in the synthetic route. As such, the ortho ester of 
acid 2.35 was formed (2.36; Scheme 2.5). Ozonolysis and addition of vinyl Grignard was 
not successful; however, the failure of this process was possibly due to cleavage and 
decomposition of the ortho ester. To further simplify the process, the acid was protected 
by reduction to the alcohol (2.38) and formation of the silyl ether 2.39. While this was 
not ideal for an eventual synthetic route for reasons of step/atom/redox economy,17–20 a 
silyl ether would be more stable to future conditions and help determine the feasibility of 
the route. In this case, the result was that a one-flask ozonolysis and Grignard reaction 
was possible, with an adequate yield of diol 2.40 (59%). 
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Scheme 2.5. Synthesis of Diol 2.40. 
With diol 2.40 in hand, only a double dehydration was required to form the 
desired tetraene 2.41. Although simplistic on paper, this reaction is complicated by a 
number of features. First, after one of the hydroxy groups was converted into a leaving 
group, the remaining alcohol rapidly cyclized to form a cyclic ether. Another issue was 
that the targeted tetraene was going to be especially prone to isomerization to the fully 
conjugated system or oligomerization/polymerization due to the high percentage of 
conjugated alkenes present. Therefore, strongly acidic or basic conditions were 
considered to be incompatible with the tetraene, but mild acids or bases would be 
required for elimination. Unfortunately, all of the conditions attempted for the double 
elimination, including Appel conditions61 and MsCl, led to only cyclization, 
polymerization, or other routes of decomposition. The conclusion that was gleaned from 
these failed approaches was that the synthesis of the bis-diene was not as simple as 
initially considered and that more neutral conditions would be required for its generation. 
To solve this problem, we decided to move into the area of organometallics. 
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3.2 Decarboxylation Approach 
While considering the many metal-catalyzed options to generate the bis-diene, the 
opportunity to utilize a palladium(0)-catalyzed allylic decarboxylation appeared 
especially attractive (Scheme 2.6). Metal-catalyzed allylic substitutions and 
decarboxylative couplings have been examined and have been the topics of reviews.62,63 
For the system that fits for the requisite bis-diene (2.21), the ideal decarboxylation 
precursor would be a linear (2.42) or a branched (2.43) pentadienyl dienoate. Although 
there are numerous reports of allylic substitutions, there were only very limited reports of 
pentadienylic substitutions,64 and no reports of decarboxylative couplings with a 
dienoate. These facts resulted in this route having a higher level of risk. However, since 
previous routes were unsuccessful, and necessity is the mother of invention, we felt that 
this process was worth exploring. 
 
Scheme 2.6. Retrosynthesis of 2.21. 
Before dedicating efforts to the synthesis of the specific system required, a model 
system was again utilized (Scheme 2.7). As such, butyryl chloride was reacted with 
divinyl carbinol, the resulting ester (2.45) was deprotonated and reacted with acrolein, 
and elimination via the mesylate yielded pentadienyl dienoate 2.47 as a mixture of E and 
Z isomers. Gratifyingly, after subjecting ester 2.47 to Pd(PPh3)4 in dichloromethane at 50 
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°C, significant amounts of decarboxylated product were formed. This was not only the 
first Pd-catalyzed allylic decarboxylative coupling of a system of this type, but also a 
major breakthrough in this project since we finally synthesized the bis-diene. This 
decarboxylative coupling is unique for several reasons, including requiring an equivalent 
of water for success.  This will be discussed in greater detail in Section 5. Although the 
resultant tetraene 2.49 was relatively volatile (C11H16), it could be characterized and was 
used to test the viability of the next Rh(I)-catalyzed cycloaddition reaction. A definitive 
yield wasn’t obtained for reasons of scale and volatility; however, it was clear that the 
cycloaddition was successful. Given the success of these two key reactions, we decided 
to generate the structures required for the actual system. 
 
Scheme 2.7. Model Study for Tetraene Formation. 
4. Synthesis of Clinprost and Analogues 
4.1 Synthesis of the Bicyclic Core 
Our synthetic plan (Scheme 2.8) initiated with the preparation of the key bis-diene 
building block of clinprost (2.3) from commercially available, inexpensive starting 
materials. As such monoesterification of pimelic acid with divinyl carbinol easily 
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accessed ester 2.52 using DCC and DMAP. The use of excess pimelic acid allowed for 
scalability, efficiency and separability using the insolubility of pimelic acid and 
dicyclohexyl urea in hexane. This esterification was followed by aldol condensation with 
acrolein at the alpha position of the ester using 3 equivalents of solid LiHMDS. The 
resulting compound (2.53) was converted to its methyl ester (2.54) using diazomethane 
and finally dehydration via the mesylate with DBU afforded pentadienyl dienoate 2.55. 
 
Scheme 2.8. Synthesis of Tetraene Precursor 2.55. 
Ester 2.55 was then subjected to a Pd(0)-catalyst which resulted in a simultaneous 
decarboxylation of the allyl ester and allylic rearrangement to form the building block of 
this synthesis (2.56; Scheme 2.9). It was determined that bis-diene 2.56 was relatively 
stable when pure, but trace impurities sometimes led to rapid polymerization. For this 
reason, bis-diene 2.56 was typically used in subsequent reactions within one week. Bis-
diene 2.56 was reacted with 10 mol % of a rhodium (I) catalyst under carbon monoxide 
atmosphere, followed by reduction using sodium borohydride, to yield the completed 
bicyclic core (2.58). 
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Scheme 2.9. Synthesis of the Clinprost Core. 
There is a major increase in the molecular complexity for this [2+2+1] 
cycloaddition reaction during which both rings are assembled and four stereocenters are 
set with the required relative stereochemistry after in situ reduction from the convex face 
of the bicycle using sodium borohydride (Scheme 2.9). The mechanism through which 
this [2+2+1] reaction proceeds has been previously studied (Scheme 2.10).65 When the 
rhodium catalyst comes into contact with the olefins, it undergoes an oxidative 
cyclization and forms the first ring of the bicycle as seen in intermediate 2.59. The 
rhodium then inserts one of its carbonyl ligands into the rhodacycle 2.59, thereby 
expanding it by one carbon (2.60). Finally, reductive elimination occurs and the reduced 
rhodium species is released from intermediate (2.60). The carbon monoxide atmosphere 
under which the reaction is kept allows coordination of another carbonyl ligand and the 
rhodium catalyst is then ready to reenter the catalytic cycle. The [2+2+1] cycloaddition of 
diene-enes,65 diene-ynes66 and diene-allenes67 has been reported, however, our synthesis  
of clinprost is the first report of a diene-diene [2+2+1] cycloaddition. 
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Scheme 2.10. Rhodium-Catalyzed Diene-Diene [2+2+1] Cycloaddition. 
The yield for the diene-diene [2+2+1] reaction is low in part because only the Z-
isomer of bis-diene 2.56 reacts to give bicyclic ketone 2.57 while the E-isomer remains 
unreacted. Moreover, ketone 2.57, formed after the cycloaddition, isomerizes quickly to 
the more stable and undesired α,β-unsaturated ketone isomer (2.62; Scheme 2.11). 
Different conditions were examined in order to maximize the yield of the [2+2+1] 
carbonylative cycloaddition. The reaction could be performed in triflouroethanol (TFE), 
despite the quick isomerization of the desired product, but dichloroethane (DCE) worked 
most efficiently for this reaction. Running the reaction for longer than 9 hours at 80 °C 
increased the isomerization to the undesired enone (2.62). Different temperatures were 
screened only to obtain completely or mostly the undesired product. The loading of the 
rhodium catalyst was increased to more than 10 mol % without showing an effect on the 
yield. An additive, silver hexaflouroantimonate, was also tried, but mainly the isomerized 
undesired product resulted. It was found that running this reaction at 70 °C in DCE for 8 
hours gives the highest yield at 22%. 
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Scheme 2.11. Isomerization of the Bicyclic Ketone. 
4.2 Synthesis of Clinprost and Analogues from the Bicyclic Core 
With the bicyclic core (2.58) in hand, different compounds could be synthesized 
from the same penultimate intermediate, allowing for late-stage diversification. Different 
ω-sidechains were installed via ruthenium(II)-catalyzed cross metathesis using different 
alkenes (Scheme 2.12). Since this type of reaction was previously reported in a very 
similar structure by Sheddan and Mulzer,57 we were confident that the reactions would be 
successful.  
  
Scheme 2.12. Introduction of ω-sidechains via Cross Metathesis. 
The alkenes used were either commercially available (2.65 – 2.67) or could be 
accessed by one or two steps (2.63 and 2.64; Scheme 2.13). As shown, using enzymatic 
resolution of racemic 1-octen-3-ol (2.68),68 we were able to synthesize alkenes 2.69 and 
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2.70 with high enantioselectivity. When alkenes 2.69 or 2.70 were reacted with bicyclic 
core 2.58, two diastereomers were produced that were separated by column  
chromatography to get protected analogues 2.63 and 2.64 with high enantiopurities. 
 
Scheme 2.13. Resolution of Allylic Alcohol 2.68. 
Hydrolysis of the acetate group in compounds 2.63 and 2.64 (Scheme 2.14) gave 
the two analogues, clinprost (2.3) and its C15-epimer (2.72) in nine total steps. The deoxy 
analogues (2.65 - 2.67) required only seven total steps, which is less than half as many as 
previously reported analogues. Clinprost, its epimer, deoxyclinprost (2.65) and the 
bicyclic core (2.58) were tested for their neuroprotective ability in the lab of Dr. Rona 
Giffard at Stanford Medical School. The Giffard lab tests neuroprotection by a model of 
ischemia using cortical neurons isolated from embryonic mouse brains. They use primary 
cultures to more closely approximate normal neurons using assays that mimic ischemic 
conditions. The compounds that were synthesized were found to be less active than 
isocarbacyclin (2.4), the free acid of clinprost. Specifically, clinprost was neuroprotective 
at 5 µM concentration, but only when the injury to the nerve cells was reduced to 
moderate levels. This indicates that free acid is required for activity. Isocarbacyclin (2.4), 
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the free acid of clinprost, and other analogues with the free acid moiety could be obtained 
by hydrolysis of the ester. Hydrolysis was previously reported using NaOH in methanol  
(Scheme 2.12).52 
 
Scheme 2.14. Ester Hydrolysis of Clinprost Analogues. 
4.3 Efforts for the Synthesis of Saturated Bicyclic Analogues 
It was thought that a new type of analogue that does not contain the endocyclic 
double bond could be synthesized in almost exactly the same manner. Instead of the 
mono-esterified pimelic acid undergoing the aldol reaction with acrolein, an allyl group 
could be installed via a simple enolate alkylation reaction. Subsequent methylation, 
elimination, decarboxylation, cycloaddition, and cross-metathesis steps could be 
performed in the same manner as before with the result being a more saturated analogue  
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(2.76; Scheme 2.15). The synthesis to generate diester 2.73 proceeded as planned,  
however, numerous decarboxylation conditions failed. 
 
Scheme 2.15. Proposed Synthesis of Ring-Saturated Analogues of Clinprost. 
As mentioned earlier, we reported the first allylic decarboxylation reaction of 
pentadienyl esters.56 We considered that the pentadienyl group was assisting with 
reactivity so it was believed that the palladium-catalyzed decarboxylation of diester 2.73 
would be as successful as the previous example. Interestingly, when saturated diester 
2.73 was subjected to the same decarboxylation conditions as those published for the 
synthesis of clinprost (2.3), the expected product was not observed. Multiple trials using 
more forcing conditions were conducted and all yielded the same result; the starting 
material rearranged to the linear pentadienyl ester but did not undergo decarboxylation. 
This result gave further evidence to the uniqueness of the previously described 
decarboxylation that will be discussed in greater detail in the following section. 
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5. Exploration into the Novel Decarboxylation Reaction 
Decarboxylation reactions have a rich history in organic synthesis, including 
syntheses of cubane and morphine (Figure 2.8).69 However, classical decarboxylations 
typically use high temperatures and/or strong acids or bases.70–72 In more recent years, 
many metal-catalyzed decarboxylations have been reported (Figure 2.8)62 with less harsh 
conditions, although anion-stabilizing groups are still required. As mentioned earlier, we 
have demonstrated that bis-allylic dienoate systems could be decarboxylated with the bis-
allylic group rearranging to a linear pentadienyl moiety. It was also found later that this 
decarboxylation can take place at room temperature instead of heating to 50 °C and 
without the need of an anion-stabilizing group (Figure 2.10). Due to the potential impact 
of the decarboxylative coupling observed, we decided to study the reaction further. 
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Figure 2.8. Examples of Decarboxylation Reactions. 
The Pd(PPh3)4 catalyst was used for the model system (Scheme 2.5) as it is the 
most common Pd(0) source used in literature. It was then determined that phosphine 
ligands are required for the reaction since Pd2(dba)3·CHCl3 was an inactive catalyst until 
PPh3 was added into the reaction mixture. Another aspect to this system is the importance 
of water for the reaction. Originally, we found that a fresh bottle of Pd(PPh3)4 had lower 
yields than an older bottle. After screening a variety of impurities, including 
triphenylphosphine oxide, we found that when one equivalent of water was added to the 
reaction, decarboxylation was once again achieved. Other protic sources (e.g. TFE, 
MeOH, tBuOH) had similar effects; however, H2O was superior. Different solvents were 
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screened, including THF, DMF, DMSO, toluene and others, to show that DCM or 
chloroform work optimally for the novel decarboxylation.  
Further examples illustrating the usefulness of this novel decarboxylation, were 
developed by modifying the dienoate and pentadienyl groups (Scheme 2.16). 
Surprisingly, these reactions can be performed intramolecularly or intermolecularly. 
Screening different groups, such as alkenes, aromatics, cyclopropanes, alkynes and 
alkanes, instead of dienoate or pentadienyl groups, demonstrated that all these moieties 
failed to decarboxylate. This shows that both the diene and pentadienyl systems are 
required for the novel decarboxylation (Figure 2.9). 
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Scheme 2.16. Examples of Alkylative Inter- and Intramolecular Decarboxylations. 
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Figure 2.9. Unsuccessful Substrates for Decarboxylation. 
As noticed from the unsuccessful substrates of this novel decarboxylation (Figure 
2.9), this reaction requires the presence of both the dienoate and pentadienyl groups to 
work. Although many substrates failed to decarboxylate, these results gave us insights 
into the structural constraints of the process. Future efforts will be focused, on 
experimental and computational evaluation of potential mechanisms for the reaction  
using our current results as a guide. 
6. Conclusion 
The total synthesis of clinprost (2.3) in nine total steps and analogues synthesis in 
seven total steps is described utilizing inexpensive and commercially available starting 
materials (Figure 2.10). Although the first two approaches failed, we developed and 
designed two new reactions for the successful synthetic route: a decarboxylation of 
pentadienyl dienoate systems and a [2+2+1] cycloaddition of bis-diene systems. These 
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new reactions led to a rapid increase in the molecular complexity to afford the bicyclic 
core with four stereocenters as desired. This bicyclic core was used in a late-stage cross 
metathesis reaction to synthesize analogues with different ω-sidechains and to decrease 
the total number of steps to nine or fewer steps instead of 15 or more steps in previous 
syntheses. Some of the analogues had more simplified sidechains, which further 
shortened the synthetic route. We are currently exploring the synthesis of future 
analogues based on the same bicyclic core. Furthermore, the developed novel 
decarboxylation is being seperatly optimized to be used for the synthesis of other 
pentadienoate substrates. 
 
Figure 2.10. Utilization of Step-Saving Techniques in the Synthesis of Clinprost and 
Simplified Analogues.
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CHAPTER III 
SYNTHESIS AND BIOLOGICAL EVALUATION OF NEUROPROTECTIVE  
AGENTS AGAINST STROKE 
1. Background and Significance 
 Stroke is one of the leading causes of death and has been known to cause serious 
injuries to many people.1 Each year around 800,000 people in the United States have a 
new or recurrent stroke according to the statistics compiled by researchers of the 
American Heart Asssociation.2 On average someone dies every 4 minutes in the United 
States because of stroke. Between the two types of stroke, hemorrhagic and ischemic, 
ischemic stroke accounts for the majority with about 87% of the strokes.2–4 Ischemic 
stroke is caused by occlusion of a blood vessel in the brain which leads to reduced blood 
supply and availability of oxygen and glucose to the affected area in the brain.5,6 This 
deprivation in blood flow is followed by a dilation of blood vessels around the ischemic 
area to restore blood flow that is followed with a rapid influx of reactive oxygen species, 
a process known as reperfusion.6–10 This places the neuronal cells at a risk of further 
damage and limits their recovery.  
Despite decades of research, treatment options for ischemic stroke remain limited. 
Currently the only FDA-approved ischemic stroke therapy is tissue plasminogen 
activator, also known as Activase®, which has a limited time window.6,7 Other medicines 
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that are available in the market are only used as preventative therapies for protection 
against platelet aggregation, such as clopidogrel or against blood clotting such as 
warfarin. Therefore, the search for novel therapeutics that have the potential to protect 
brain tissue from this damage is urgent.6,10 Two of the promising neuroprotective agents 
are isocarbacyclin (3.2) and clinprost (3.1). Clinprost (3.1) is the methyl ester of 
isocarbacyclin (3.2) and found to be hydrolyzed by esterases in the brain to form 
isocarbacyclin (3.2; Scheme 3.1).11 They are both chemically stable prostaglandin 
analogues (PGI2)
12 and are found to have a highly potent neuroprotective effect against 
ischemic stroke in animal models by increasing the blood flow in the ischemic area and 
preventing platelets aggregation.7,11,13–16 
 
Scheme 3.1. Clinprost (3.1) Hydrolyzes to Isocarbacyclin (3.2) in Brain. 
A significant amount of research on neuroprotection against ischemic stroke has 
been performed using animal models. One of the studies for the neuroprotective effect of 
isocarbacyclin (3.2) against neuronal damage in gerbils demonstrated that it prevents the 
occurrence of neuronal damage after an induced ischemic stroke.12 In this study, they 
infused saline (vehicle), isocarbacyclin (3.2, 0.12 ng/day) or isocarbacyclin (3.2, 1.2 
ng/day) for 7 days into gerbils’ brains starting 3-minutes after the induced ischemic 
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stroke (Figure 3.1). It was found that there was a significant difference in the neuronal 
density between the vehicle and isocarbacyclin infusion (3.2, 1.2 ng/day) with 137 
cells/mm and 197 cell/mm respectively (Figure 3.1). This indicated that the treatment  
with isocarbacyclin (3.2) had significant results in preventing the ischemia. 
 
Figure 3.1. Effects of Isocarbacyclin (3.2, TEI 7165) on Neuronal Density of the Brain 
Region in Gerbils with 3-min Forebrain Ischemia. This graphic was reproduced with a  
permission from Elsevier.12 
 Another part of the study showed photomicrographs of a normal brain of gerbils 
(Figure 3.2; A), an ischemic brain with a vehicle infusion (Figure 3.2; B) and an ischemic 
brain with isocarbacyclin infusion (Figure 3.2; C), which significantly shows the 
neuroprotection effect of isocarbacyclin (3.2) on a gerbil neuronal cells after an induced 
ischemic stroke. 
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Figure 3.2. Photomicrographs of a Gerbil Brain with or without 3-min Ischemia. A: 
Normal Animal with Vehicle Infusion. B: Ischemic Animal with Vehicle Infusion. C: 
Ischemic Animal with isocarbacyclin (3.2) (1.2 ng/day) infusion. This graphic was  
reproduced with permission from Elsevier.12 
 A few studies showed that isocarbacyclin (3.2) was found to have a great potency 
to a subtype prostaglandin receptor (prostacyclin receptor), IP2, that is expressed in the 
central nervous system and distinguished from the peripheral type receptor, IP1, found in 
the peripheral nervous system.7,8,16–18 This finding is in agreement with the 
neuroprotection action of isocarbacyclin (3.2), however the mechanism of the IP2 
receptor ligand has not been clarified. The biological activity of this promising compound 
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has been only limited to few studies which were performed on animal models due to its 
complex structure that limited its synthesis. The Croatt research group reported the 
synthesis of clinprost (3.1) in only 9 steps,19,20 as will be described herein, which has 
been used in the synthesis of clinprosts’ free acid, isocarbacyclin (3.2), and its analogues  
in 10 or fewer steps. 
2. Results and Discussion 
2.1 Synthesis of Isocarbacyclin and Analogues 
 Having this valuable biological activity, clinprost and isocarbacyclin were 
synthesized by several groups with diverse approaches, however, most were 20 or more 
steps with the shortest reported synthesis requiring 15 steps starting from commercially 
available materials.21–30 Isocarbacyclin and other analogues were synthesized, as will be 
described herein, by coupling different alkenes to the same bicyclic building block (3.10; 
Scheme 3.2), which was made in only 6 steps from commercially available materials. 
This route design allowed for a late-stage diversification by using a cross-metathesis  
reaction.  
2.1.1 Synthesis of Bicyclic Core (3.10) 
 The step-economical synthesis of clinprost (3.1) reported by the Croatt group19,20 
has been used to make isocarbacyclin and other analogues having different ω-side chains 
from the same bicyclic core (3.10; Scheme 3.2). The synthesis of the core begins with 
reacting excess pimelic acid (3.3) with bisallylic alcohol (3.4) to get monoester 3.5 as a 
major product followed by aldol condensation with acrolein. A limitation in the second 
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step was the quick polymerization of acrolein during the reaction workup and 
purification. Prior researchers in our group tried various conditions to find that using 
LiHMDS in THF as a base gave the maximum yield of 15%. Later we found that using 
solid LiHMDS increased the yield to 72%.  
  
Scheme 3.2. Synthesis of the Bicyclic Core (3.10). 
 The resulting acid (3.6) was subjected to methylation and dehydration to get ester 
(3.8) that was subjected to Pd0 which results in a simultaneous decarboxylation of the 
allyl ester and allylic rearrangement to form tetraene (3.9). This new type of 
decarboxylation was studied in more detail as will be described later (Chapter IV). 
 Tetraene (3.9) is then reacted with a RhI catalyst under carbon monoxide atmosphere in a 
bis-diene [2+2+1] cycloaddition reaction followed by an in situ reduction. The four 
stereocenters of bicycle 3.10 are set in the same manner as in isocarbacyclin (3.2). 
Although [2+2+1] reactions are known for alkynes and alkenes,31–36 allenes and dienes,31 
or alkenes and dienes,37,38 this is the first [2+2+1] cyclocarbonylation of tethered dienes. 
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However, the yield is low as only the Z-isomer reacts to give bicycle 3.11 while the E-
isomer does not react. Moreover, ketone 3.11 isomerizes quickly to the more stable and 
undesired isomer (3.12, Scheme 3.3). 
 
Scheme 3.3. Bis-diene [2+2+1] Cycloaddition Reaction. 
 Different conditions were screened in order to more efficiently form the desired 
product (3.10; Table 3.1). 2,2,2-Trifluoroethanol (TFE) and dichloroethane (DCE) were 
previously found to work well with this type of reaction.37,38 However, using TFE as a 
solvent in this case gives mostly the undesired isomerized product (3.12) with a low 
selectivity compared to DCE (entries 1-6). Having DCE as a solvent, different catalytic 
amounts of RhI catalyst were screened to find that increasing the catalytic loading had no 
effect on the yield or increasing the selectivity for the desired product (3.10, entries 7, 8). 
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It was also shown that this reaction is time dependent (entries 9-12), as running the 
reaction in DCE and 10 mol % catalyst less than 6 hours will give only traces of the 
product (3.10) and more than 10 hours will cause the product to isomerize. Other 
different conditions were screened by changing the temperature and time to find that 
running the reaction for 8-10 hours at 70 °C provided the best yield (22%, entry 13) over 
the 2 steps. The yield for this step led us to develop a route for a different type of 
analogues where the double bond in the tetraene derivative is locked in the Z-form only. 
This will be discussed later in more details in this chapter (section 2.3). 
Table 3.1. Different Conditions for [2+2+1] Cycloaddition.  
Entry Solvent Temperature 
Catalytic 
Amount 
Time Product 
Yield of 
3.10 
1 TFE 60 °C 10 mol % 40 min 3.12 -- 
2 
DCE/TFE, 
1:1 
80 °C 10 mol % 15 min 3.11+3.12 Traces 
3 
DCE/TFE, 
1:7 
80 °C 10 mol % 5 min 3.11+3.12 Traces 
4 
DCE/TFE, 
1:9 
80 °C 15 mol % 7 min 3.11+3.12 8% 
5 
DCE/TFE, 
1:9 
80 °C 20 mol % 10 min 3.12 -- 
6 DCE/TFE, 80 °C 10 mol % 3 hr 3.11+3.12 Traces 
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10:1 
7 DCE 80 °C 10 mol % 8 hr 3.11+3.12 11% 
8 DCE 80 °C 25 mol % 8 hr 3.11+3.12 7% 
9 DCE 80 °C 10 mol % 2 hr 3.11+3.12 Traces 
10 DCE 80 °C 10 mol % 5 hr 3.11+3.12 Traces 
11 DCE 80 °C 10 mol % 10 hr 3.11+3.12 9% 
12 DCE 80 °C 10 mol % overnight 3.11+3.12 Traces 
13 DCE 70 °C 10 mol % 8 hr 3.11+3.12 22% 
aReaction Conditions: Bis-diene (3.9, 1eq), under CO atmosphere, in solvent (0.1 M). 
2.1.2 Synthesis of Isocarbacyclin and Analogues (3.2, 3.15 - 3.19) 
To complete the synthesis of isocarbacyclin, a RuII-catalyzed cross metathesis 
was utilized to attach the ω-side chain, (S)-3-acetoxy-oct-1-ene (3.13), which was 
synthesized using an enzymatic resolution of racemic 1-octen-3-ol as shown in Chapter 
II, section 4.2.28 This cross metathesis was followed by a hydrolysis using NaOH to 
remove the protecting groups and result in isocarbacyclin (3.2) and its diastereomer (dia-
3.2) in an enantioselective fashion (Scheme 3.4). Although the hydrolysis reaction 
appears simple, many trials were carried out in order for the reaction to work. It was 
found that the resulting analogues decomposed to an unknown byproduct(s). Therefore,  
the reaction needs careful workup and purification to obtain the product. 
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Scheme 3.4. Enantioselective Synthesis of Isocarbacyclin (3.2) and its Diastereomer  
(dia-3.2). 
 A cross-metathesis approach has been successfully applied using different 
terminal alkenes followed by hydrolysis of the methyl ester to afford other analogues 
(3.15 - 3.19) from the same bicyclic core (3.10; Scheme 3.5). Moreover, bicyclic core 
3.10 was directly subjected to hydrolysis since it is considered as another analogue for 
isocarbacyclin missing the ω-side chain. Two commercially available alkenes, p-styrene 
and myrcene, were tested in the cross metathesis as well. However, only homocoupling 
byproducts were observed as a result of the high conjugation and the synthesis of 
analogues 3.20 and 3.21 were unsuccessful. 
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Scheme 3.5. Successful (3.15 - 3.19) and Unsuccessful Analogues (3.20 - 3.21) of  
Isocarbacyclin. 
2.1.3 Biological Evaluation of Isocarbacyclin and its Bicyclic Analogues 
 Isocarbacyclin and bicyclic analogues (3.2, 3.15 - 3.19) were sent recently to the 
Giffard lab, where they will be tested in a neuroprotection model using cortical neurons 
isolated from embryonic mouse brains. They use primary cultures to more closely 
approximate normal neurons than is possible using cell lines. It has previously been 
shown that isocarbacyclin derivatives bind to and protect certain areas of the brain, with 
the cortex being one of the areas where these derivatives did bind and protect from cell 
death.17 The assays that the Giffard lab uses conditions that mimic ischemia. For the first 
assay they will examine neuroprotection from glucose deprivation, a component of 
ischemia which induces oxidative stress, assessing the isocarbacyclin analogues over a 
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range of concentrations. With the second assay, cells will be deprived of both glucose and 
oxygen. This is a more severe stress, which more closely mimics ischemia and  
reperfusion. 
2.2 Efforts toward the Synthesis of Tricyclic Isocarbacyclin Analogues 
During the synthesis of isocarbacyclin (3.2) and its analogues, our main focus was 
on optimizing the [2+2+1] cycloaddition of tetraene 3.9 that yields the bicyclic building 
block (3.11) for these analogues. We were able to maximize the yield to 22% as only the 
Z-isomer of the tetraene reacts in the cycloaddition while the E-isomer does not (Scheme 
3.6; A). This limitation in the previous synthesis led us to design a new synthetic pathway 
where we can get a bis-diene with the double bond locked only in the Z-isomer to end up 
with a tricyclic core (3.23) for a new type of isocarbacyclin analogues (Scheme 3.6; B). 
Moreover the tricyclic analogues position the α-side chain in a manner similar to 
prostacyclin (Scheme 3.6; B). 
 
Scheme 3.6. Bicyclic (3.11) vs. Tricyclic (3.23) Building Blocks.  
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A model system for the tricyclic analogues was first developed (Scheme 3.7) to 
test if the decarboxylation and cycloaddition reactions will be successful. The model 
system synthesis starts from the commercially available β-ketoester 3.25 that undergoes 
mesylation using MsCl to get mesylate 3.26. Mesylate 3.26 was found to decompose on 
standing at ambient temperature for several hours. It was, therefore, taken directly to the 
Stille coupling without further purification39 to afford dienoic ester 3.27 upon reacting  
with vinyl stannane.40,41  
 
Scheme 3.7. Synthesis of the Tricyclic Core (3.30) in the Model System. 
Different conditions were screened to optimize the coupling reaction (Table 3.2). 
The optimization started with increasing the catalytic loading of Pd(PPh3)4 from 5 mol % 
to 10 mol % (entries 1, 2) with no significant changes on the yield. On the other hand, a 
minor change on the yield was noticed when increasing the equivalents of vinyl stannane 
from 1.5 to 2.0 equivalents (entries 3-4). Increasing the equivalents of LiBr (entry 5) was 
found to decrease the yield. Having the equivalents of the reactants and catalyst 
optimized, different temperatures were screened using the microwave reaction (entries 6-
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7) to find a huge effect when running the reaction at 90 °C to get a yield of 60%. Higher 
temperatures (entry 8) caused decomposition of the mesylate faster than the formation of 
the product. 
Table 3.2. Different Conditions for the Stille Coupling.a  
Entry Pd
0
 
Vinyl 
Stannane 
LiBr Temperature Yield 
1 5 mol % 1.2 eq 1.5 eq reflux 10% 
2 10 mol % 1.2 eq 1.5 eq reflux 12% 
3 5 mol % 1.5 eq 1.5 eq reflux 15% 
4 5 mol % 2.0 eq 1.5 eq reflux 20% 
5 5 mol % 2.0 eq 2.0 eq reflux traces 
6 5 mol % 2.0 eq 1.5 eq microwave - 80 °C 42% 
7 5 mol % 2.0 eq 1.5 eq microwave - 90 °C 60% 
8 5 mol % 2.0 eq 1.5 eq microwave - 100 °C 17% 
aReaction Conditions: Mesylate (3.26, 1eq), in THF (0.1 M). 
 The resulting ester (3.27) from the Stille coupling was then subjected to 
hydrolysis with LiOH to afford dienoic acid (3.28). A one-pot reaction for Stille coupling 
and hydrolysis was successful to yield dienoic acid 3.28, however, many trials to purify 
this compound using different solvents were unsuccessful because of streaking of the 
stannane byproduct. Dienoic acid 3.28 can undergo a decarboxylative coupling with 
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bisallylic alcohol (3.4) when subjected to Pd0 conditions. The decarboxylated product 
(3.29) was subjected to RhI catalyst under a carbon monoxide atmosphere with several 
different conditions to yield only traces of tricycle 3.30 (Table 3.3). Tricycle (3.30) was 
not fully characterized due to the volatility of the starting material and the isomerization 
of the product; however it was clear that both reactions, decarboxylation and 
cycloaddition, were successful which validated moving from the model system to the real 
synthetic route for the tricyclic analogues. 
Table 3.3. Different Conditions for Cycloaddition of Tetraene (3.29).a   
Entry Catalyst Temp Additives Results 
1 [RhCl(CO)2]2, 10 mol % 80 °C -- no reaction 
2 [RhCl(CO)2]2, 20 mol % 80 °C -- traces
b 
3 [RhCl(CO)2]2, 20 mol % rt AgSbF6, 10 mol % no reaction 
4 [RhCl(CO)2]2, 20 mol % 80 °C AgSbF6, 10 mol % traces 
5 RhCl(CO)(PPh3)2, 20 mol % 80 °C AgSbF6, 10 mol % traces 
aReaction Conditions: Tetraene (3.29, 1 eq), under CO atmosphere, in DCE (0.1 M). bThe  
majority of the staring material was recovered. 
Having the model system working, a synthetic scheme was proposed (Scheme 
3.8) that starts with reacting β-keto ester (3.25) with methyl bromoacetate (3.31) in order 
to get diester (3.32) where this forms the α-side chain of the final analogues. Multiple 
conditions were attempted for this reaction with no product observed (Table 3.4). The  
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reactions resulted in either an unknown byproduct or the methyl acetate group added α to  
the ester functionality (3.33). 
  
Scheme 3.8. First Proposed Synthesis for the Tricyclic Isocarbacyclin Analogues.  
Table 3.4. Different Conditions for the First Step in the Tricyclic Isocarbacyclin 
Analogues Synthesis.a 
Entry Base Temperature Time
b 
Results 
1 LiHMDS (2 eq) -78 °C 20 min Unknown byproduct 
2 
NaH (1 eq) + 
LiHMDS (1 eq) 
-78 °C - rt 20 min Unknown byproduct 
3 LiHMDS (2 eq) -78 °C 20 min 3.33 
4 KHMDS (2 eq) -78 °C 20 min 3.33 
5 KHMDS (2 eq) -78 °C 2 hr 3.33 
6 KHMDS (2 eq) -78 °C - rt 2 hr No reaction 
aReaction Conditions: β-keto ester (3.25, 1 eq), methyl bromoacetate (3.31, 1 eq), in THF 
(0.1 M). bTime before the addition of 3.31. 
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Another synthetic scheme for the tricyclic core (3.34) was developed after the 
first step failed in the previous synthesis (Scheme 3.9). For this synthesis, we tried to 
attach the acetyl functionality before the methyl ester group; cyclopentanone (3.35) was 
reacted with t-butyl bromoacetate (3.36) to afford ketone 3.37. Ketone 3.37 then reacts 
with methyl chloroformate, using LiHMDS as a base to provide diester 3.38. After a few 
trials changing the time for this reaction and getting an unknown byproduct in this step, it 
was found that leaving the reaction to warm to room temperature for more than four 
hours will cause the decomposition of the product to an unknown byproduct. As a result, 
the reaction was left in the cooling bath for four hours to optimally synthesize the diester 
(3.38). In this way, we were able to get the analogues similar to the previous synthesis. 
As a difference the structure has two orthogonal carboxylic acid protecting groups, which 
make it beneficial for this route later, as we can selectively hydrolyze one of them.  
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Scheme 3.9. Synthesis of Tetraene Building Block (3.42) for the Tricyclic Isocarbacyclin  
Analogues. 
 The resulting diester (3.38) was expected to act similarly in the mesylation as in 
the model system. Unfortunately, another unknown byproduct formed in addition to the 
desired mesylate (3.39). Different conditions were screened (Table 3.5) to form the 
mesylate (entries 1-6), bromide (entries 7, 8) or triflate (entries 9-11) derivatives that 
could work as a starting material for the next Stille coupling step. All trials either resulted 
in a byproduct along with the product in the case of the mesylate and the bromide or no 
reaction in the case of the triflate.  
Table 3.5. Different Conditions for the Synthesis of Stille Coupling Starting Material in 
the Real System of the Tricyclic Analogues.a 
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Entry X Reactant Additive Temp Solvent Time 
1 OMs MsCl (2.6 eq) Et3N (4.9 eq) 0 °C - rt DME overnight 
2  MsCl (2.6 eq) Et3N (4.9 eq) 0 °C - rt DME 4 hr 
3  MsCl (6.6 eq) Et3N (6.9 eq) -40 °C - rt DME overnight 
4  MsCl (5.6 eq) Et3N (10.9 eq) -20 °C - rt DME 30 min 
5 
 
MsCl (7.6 eq) Et3N (14.9 eq) 0 °C - rt THF overnight 
6 
 
MsCl (2.6 eq) NaH (1.5 eq) 0 °C - rt THF overnight 
7 Br 
oxalyl bromide 
(1.5 eq) 
DMF (1.3 eq) 0 °C - rt CH2Cl2 4 hr 
8 
 
oxalyl bromide 
(1.5 eq) 
Et3N (2.0 eq) 0 °C - rt CH2Cl2 overnight 
9 OTF 
Comins’ reagent 
(2.5 eq) 
NaH (1.5 eq) 0 °C - rt THF 4 hr 
10 
 
Comins’ reagent 
(2.5 eq) 
NaH (1.5 eq) 0 °C - rt THF overnight 
11 
 
Comins’ reagent 
(1.4 eq) 
LiHMDS  
(1.2 eq) 
-78 °C - rt THF overnight 
aReactions Conditions: Diester (3.38, 1 eq), solvent (0.1 M). 
 At that point we decided to move forward although mesylate (3.39) was not fully 
characterized. The crude mesylate product was subjected to Pd0 catalysis for a Stille 
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coupling in the same way as in the model system to generate dienoic ester 3.40 in a 20% 
yield over the two steps. Dienoic ester 3.40 was subjected to LiOH to hydrolyze 
selectively the methyl ester and afford dienoic acid (3.41) that reacts with bisallylic 
alcohol (3.4) to get the decarboxylated tetraene (3.42). 
 Tetraene (3.42) was expected to react in the next step as in the model system. 
However; it did not react when subjected to [RhCl(CO)2]2 under carbon monoxide 
atmosphere at 80 °C. On the other hand, reacting tetraene 3.42 with [RhCl(CO)2]2 
catalyst at room temperature and AgSbF6 as an additive resulted in a different reaction 
with an unknown mechanism and afforded structure 3.45 (Scheme 3.10). The molecular 
formula for the resulted structure (3.45) was determined to be C14H18O2 by its HRESIMS, 
which required 6 degrees of unsaturation similar to tetraene 3.42. The 1H and 13C NMR 
spectra of 3.45, interpreted with the aid of COSY, HSQC and HMBC spectra, revealed 
the presence of one CH3 [δH 0.86; δC 7.7], 5 CH2 including one vinylic [δH 5.19; δC 
118.2] and 4 aliphatic [δH 2.90, 2.63, 2.34, 2.14 and 1.85; δC 38.2, 38.1, 28.6 and 24.8], 5 
CH including 4 vinylic [δH 6.59, 6.12 and 5.55 (2H); δC 131.8, 130.9, 128.4 and 128.1] 
and one aliphatic [δH 2.82 (dddd); δC 39.5] and 3 fully substituted carbons which are one 
carbonyl  [δC 176.9], one vinylic [δC 142.3] and one aliphatic [δC 101.9]. Moreover 1H 
and 13C NMR spectra of 3.45 shows the formation of two E and Z isomers at C9-C10 
double bond in a 4.0:1.0 ratio.   
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 Scheme 3.10. Cyclization of Bis-Diene 3.42 to Afford the Unanticipated Bicycle 3.45. 
The COSY correlations of H13 and H14 suggests the presence of the ethyl group. 
Additionally, the chemical shifts and sequential COSY correlations of H8, H9, H10, H11 
and H12 suggests the presence of a pentadienyl chain. The HMBC correlations of H2a and 
H2b/C-1, H2a, H2b/C-7 explains the ring connections (Figure 3.3; A). The HMBC 
correlations of H13, H14/C-7 and H13, H14/C-3 suggests that the ethyl group is on a fully 
substituted carbon and explains the way the two rings are connected. The HMBC 
correlation of H5/C-3 explains linking of a methylene to the C-3/C-4 double bond. The 
NOESY correlations of H13/H6 explains the stereochemistry of the two stereocenters 
C6/C7 (Figure 3.3; B).   
 
Figure 3.3. A: Selected Key HMBC Correlations of Structure 3.45. B: Selected Key  
NOESY Correlations of Structure 3.45. 
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3. Conclusion 
In summary, we present an enantioselective synthesis of isocarbacyclin in 10 
steps using three transition metal-catalyzed reactions including Pd0-catalyzed 
decarboxylation, RhI-catalyzed cycloaddition and RuII-catalyzed cross-metathesis. This 
synthetic approach of isocarbacyclin takes advantage of attaching an ω-side chain at a 
late stage in the synthesis, which enabled us to synthesize other analogues from the same 
bicyclic building block by attaching different alkenyl ω-side chains. A limitation of this 
synthesis is the low yield of the cycloaddition step which led us to develop a new 
synthesis for tricyclic analogues to increase the yield of that step. A model synthesis 
worked successfully for this synthesis, however, efforts toward the cycloaddition step 
failed and resulted in a different type of reaction. Future efforts toward a tricyclic 
analogue will need to reveal the carboxyl group at a later stage. 
4. Experimental and Characterization Data 
4.1 General Information 
All anhydrous reactions were performed in oven dried glassware under a nitrogen 
atmosphere. Unless otherwise noted, all solvents and reagents were obtained from 
commercial sources and used without further purification. Tetrahydrofuran (THF) and 
dichloromethane (CH2Cl2) were obtained dry from the solvent system and degassed 
under a dry atmosphere of nitrogen. 1,2-dichloroethane (DCE), dimthoxyethane (DME), 
2,2,2-trifluoroethanol (TFE) and methanol (MeOH) were obtained dry from Sigma 
Aldrich and degassed under a dry atmosphere of nitrogen or carbon monoxide. 
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Chromatographic purification was performed using silica gel (60 Å, 32-63 μm). NMR 
spectra were recorded in CDCl3 using a JEOL ECA 400 spectrometer (400 MHz for 1H, 
100 MHz for 13C, and 376.5 MHz for 19F), JEOL ECA spectrometer (500 MHz for 1H 
and 125 MHz for 13C) and an Agilent 700-NMR spectrometer equipped with a 1H 
(13C/15N) 5 mm Enhanced Cold Probe (176 MHz for 13C). Coupling constants, J, are 
reported in hertz (Hz) and multiplicities are listed as singlet (s), doublet (d), triplet (t), 
quartet (q), quintet (quint), doublet of doublets (dd), triplet of triplets (tt), multiplet (m), 
etc. High Resolution Mass Spectra were acquired on a Thermo Fisher Scientific LTQ 
Orbitrap XL MS system. Analytical GC data was collected with an Agilent 7890A gas 
chromatograph with BetaDex 110 Fused Silica Capillary Column (30 m x 0.25 mm with 
0.25 µm film thickness). GC runs were performed with a flow rate of 3 mL/min, injection 
temperature of 250 °C, and an initial oven temperature of 40 °C for 60 minutes.  The 
temperature was increased to 80 °C at a rate of 2 °C per minute, oven temperature was 
held at 80 °C for 10 minutes and finally the temperature was increased to 170 °C at a rate  
of 5 °C per minute and held at 170 °C for 5 minutes. 
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4.2 Synthesis of Isocarbacyclin and Analogues 
4.2.1 Synthesis of the Bicyclic Core, 3.10 
 
 
7-oxo-7-(penta-1,4-dien-3-yloxy)heptanoic acid, 3.5 
A solution of DCC (2.5 g, 12 mmol) in THF (15 mL) was added to a solution of 
pimelic acid 3.3 (9.5 g, 59 mmol), 1,4-pentadien-3-ol 3.4 (1.2 mL, 12 mmol), and DMAP 
(145 mg, 1.2 mmol) in THF (90 mL) slowly via an additional funnel over 3 hours. After 
48 hours, the reaction was filtered through Celite® and washed with THF. Silica gel was 
added to the concentrated mixture and the solvent was removed after which the dry 
powder was added to a silica gel column. The product was purified (70:30, hexanes/ 
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EtOAc) to yield acid 3.5 (2.1 g, 83%) as colorless oil. Rf = 0.23 (70:30, hexanes/ EtOAc). 
The NMR spectra matched previous reported data.20 
1
H NMR (400 MHz, CDCl3) δ 9.83 (bs, 1H), 5.83 (ddd, J = 16.9, 10.4, 6.0 Hz, 2H), 5.72 
– 5.69 (m, 1H), 5.31 – 5.21 (m, 4H), 2.35 (t, J = 7.5 Hz, 4H), 1.69 – 1.61 (m, 4H), 1.41 – 
1.36 (m, 2H) ppm. 
 
 
7-hydroxy-6-((penta-1,4-dien-3-yloxy)carbonyl)non-8-enoic acid, 3.6 
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To a solution of LiHMDS (2.2 g, 13 mmol) in THF (12 mL) at -78 °C was slowly 
added acid 3.5 (1.0 g, 4.4 mmol) in THF (6 mL). After stirring for 15 minutes, the 
reaction was transferred via a cannula quickly to a mixture of acrolein (2.9 mL, 44 mmol) 
in THF (22 mL) cooled to -78 °C. Additional THF (4 mL) was transferred as a wash and 
the mixture was warmed to room temperature for 15 minutes. The reaction was quenched 
by addition of saturated NH4Cl solution (10 mL). After 2 extractions with EtOAc, a 10% 
aqueous HCl was added to the aqueous layer until pH ~ 3. This addition was followed by 
2 more extractions with EtOAc. The combined organic layers were dried using Na2SO4 
and filtered. The organic layers were then concentrated and purified via silica gel 
chromatography (65:35, hexanes/EtOAc) which yielded alcohol 3.6 (0.87 g, 70%) as a 
brown oil. Two isomers are produced, diastereomer A and B. The diastereomeric ratio is 
1:1 with diastereomer A eluting early. The NMR spectra matched previous reported 
data.20 
Diastereomer A: 
1
H NMR (400 MHz, CDCl3) δ 5.86 – 5.78 (m, 3H), 5.76 – 5.72 (m, 1H), 5.34 – 5.17 (m, 
6H), 4.23 (t, J = 6.3 Hz, 1H), 2.56 – 2.50 (m, 1H), 2.32 (t, J = 7.5 Hz, 2H), 1.75 – 1.56 
(m, 4H), 1.41 – 1.32 (m, 2H) ppm. Rf = 0.67 (50:50, hexanes/EtOAc). 
Diastereomer B: 
1
H NMR (500 MHz, CDCl3) δ 5.87 – 5.79 (m, 3H), 5.72 – 5.75 (m, 1H), 5.34 – 5.18 (m, 
6H), 4.34 (t, J = 5.6 Hz, 1H), 2.57 – 2.53 (m, 1H), 2.33 (t, J = 7.3, 2H), 1.77 – 1.59 (m,  
4H), 1.44 – 1.30 (m, 2H) ppm. Rf = 0.57 (50:50, hexanes/EtOAc). 
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7-methyl 1-penta-1,4-dien-3-yl 2-(1-hydroxyallyl)heptanedioate, 3.7 
To a solution of alcohol 3.6 (705 mg, 2.5 mmol) in MeOH (25 mL) that was 
cooled to 0 °C was slowly added a 2M solution of trimethylsilyldiazomethane in diethyl 
ether (6.9 mL, 14 mmol). After 15 minutes of stirring, N2 was bubbled through the 
reaction for 20 minutes and the reaction was concentrated before purification via silica 
gel chromatography (80:20, hexanes/EtOAc). Purification yielded ester 3.7 (688 mg, 
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93%) as a yellow oil. Two isomers are produced, diastereomer A and B. The 
diastereomeric ratio is 1:1 with diastereomer A eluting early. The NMR spectra matched 
previous reported data.20 
Diastereomer A: 
1H NMR (400 MHz, CDCl3) δ 5.88 – 5.79 (m, 3H), 5.76 – 5.72 (m, 1H), 5.34 – 5.26 (m, 
3H), 5.25 – 5.22 (m, 2H), 5.21 – 5.18 (m, 1H), 4.23 (q, J = 6.4 Hz, 1H), 3.66 (s, 3H), 2.58 
– 2.50 (m, 1H), 2.45 (d, J = 4.5 Hz, OH), 2.31 – 2.27 (m, 2H), 1.77 – 1.55 (m, 4H), 1.43 
– 1.24 (m, 2H) ppm. Rf = 0.41 (80:20, hexanes/EtOAc). 
Diastereomer B: 
1
H NMR (400 MHz, CDCl3) δ 5.88 – 5.78 (m, 3H), 5.75 – 5.71 (m, 1H), 5.34 – 5.28 (m, 
3H), 5.26 – 5.23 (m, 2H), 5.19 (dt, Jd = 10.5, Jt = 1.4 Hz, 1H), 4.34 (q, Jq = 5.4 Hz, 1H), 
3.65 (s, 3H), 2.55 (quint, J = 4.0 Hz, 1H), 2.46 (d, J = 4.5 Hz, 1H, OH), 2.31 – 2.27 (m, 
2H), 1.77 – 1.55 (m, 4H), 1.44 – 1.27 (m, 2H) ppm. Rf = 0.31 (80:20, hexanes/EtOAc). 
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(E/Z)-7-methyl 1-penta-1,4-dien-3-yl 2-allylideneheptanedioate, 3.8 
To a solution of ester 3.7 (600 mg, 2.0 mmol) and triethylamine (1.1 mL, 8.1 
mmol) in CH2Cl2 (20 mL) that was cooled to 0 °C was slowly added methane sulfonyl 
chloride (0.47 mL, 6.0 mmol). After 10 minutes, 1,8-diaza\bicycloundec-7-ene (2.0 mL, 
13 mmol) was added and the reaction was allowed to warm to room temperature. After an 
additional hour, more 1,8-diazobicycloundec-7-ene (2.0 mL, 13 mmol) was added. The 
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reaction was stirred for another 18 hours after which the reaction was poured over 
saturated NaHCO3 solution and the product was extracted 3x with CH2Cl2. The combined 
organic layers were dried over Na2SO4 and concentrated before being purified via silica 
gel chromatography (90:10, hexanes/EtOAc) to yield diene 3.8 (548 mg, 97%) as a 
colorless oil. The NMR spectra matched previous reported data.20 
E Diastereomer: 
1
H NMR (400 MHz, CDCl3) δ  7.21 (d, J = 11.4 Hz, 1H), 6.65 (ddd, J = 16.8, 11.4, 10.0 
Hz, 1H), 5.88 (ddd, J = 16.9, 10.4, 5.9 Hz, 2H), 5.78 (tt, J = 5.8, 1.0 Hz, 1H), 5.59 (dd, J 
= 16.8, 1.7 Hz, 1H), 5.47 (dd, J = 10.3, 1.7 Hz, 1H), 5.31 (dt, Jd = 17.2, Jt = 1.4 Hz Hz, 
2H), 5.24 (dt, Jd = 10.0, Jt = 1.3 Hz, 2H), 3.65 (s, 3H), 2.44 (t, J = 7.6, 2H), 2.32 (t, J = 
7.4, 2H), 1.69 – 1.60 (m, 2H), 1.53 – 1.43 (m, 2H) ppm. Rf = 0.78 (70:30, 
hexanes/EtOAc). 
Z Diastereomer: 
1
H NMR (400 MHz, CDCl3) δ 7.33 – 7.23 (m, 1H), 6.41 (d, J = 11.1 Hz, 1H), 5.91 (ddd, 
J = 16.6, 10.3, 5.9 Hz, 2H), 5.85 – 5.79 (m, 1H), 5.43 (dd, J = 17.0, 1.9 Hz, 1H), 5.38 – 
5.33 (m, 3H), 5.30 – 5.26 (m, 2H), 3.69 (s, 3H), 2.40 – 2.33 (m, 4H), 1.72 – 1.64 (m, 2H), 
1.57– 1.46 (m, 2H) ppm. Rf = 0.71 (70:30, hexanes/EtOAc). 
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(6E/Z,8E)-methyl 6-allylideneundeca-8,10-dienoate, 3.9 
To a microwave vial was added ester 3.8 (40 mg, 0.14 mmol) and water (2.7 µL, 
0.15 mmol) in CH2Cl2 (2 mL). Tetrakis-(triphenylphosphine) palladium (16 mg, 0.014 
mmol) was added and the vial was sealed and purged with N2. The mixture was a bright 
orange color.  After 24 hours at room temperature, the mixture was a turbid yellow color. 
The reaction was concentrated and purified via silica gel chromatography (97:3, 
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hexanes/EtOAc) to yield tetraene 3.9 (22 mg, 76%) as a light yellow oil. Scale-up beyond 
100 mg resulted in decreased yields; however, when eight vials were run simultaneously 
and purified together, the yield remained around 70%. The NMR spectra matched 
previous reported data.20 
E Diastereomer: 
1
H NMR (400 MHz, CDCl3) δ 6.73 – 6.51 (m, 2H), 6.08 (t, J = 10.9 Hz, 1H), 5.87 (d, J = 
11.0 Hz, 1H), 5.44 (q, J = 8.2 Hz, 1H), 5.23 (dd, J = 16.9, 1.9 Hz, 1H), 5.16 – 5.10 (m, 
2H), 5.04 – 5.00 (m, 1H), 3.67 (s, 3H), 2.93 (d, J = 7.7 Hz, 2H), 2.32 (td, Jt = 7.5, Jd = 3.3 
Hz, 2H), 2.18 (t, J = 7.8 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.49 – 1.40 (m, 2H) ppm. Rf = 
0.56 (90:10, hexanes/EtOAc). 
Z Diastereomer: 
1
H NMR (400 MHz, CDCl3) δ 6.73 – 6.51 (m, 2H), 6.05 (t, J = 10.9 Hz, 1H), 5.87 (d, J = 
10.9 Hz, 1H), 5.34 (q, J = 7.5 Hz, 1H), 5.23 (dd, J = 16.9, 1.4 Hz, 1H), 5.17 – 5.09 (m, 
2H), 5.04 – 5.00 (m, 1H), 3.67 (s, 3H), 3.06 (d, J = 7.6 Hz,  2H), 2.34 – 2.30 (m, 2H), 
2.06 (t, J = 7.4 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.49 – 1.40 (m, 2H) ppm. Rf = 0.50 (90:10, 
hexanes/EtOAc). 
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Bicycle, 3.10 
To a solution of tetraene 3.9 (19 mg, 0.09 mmol) in 1,2-dichloroethane (1.2 mL) 
was added [RhCl(CO)2]2 (3.5 mg, 0.009 mmol) before purging thoroughly with CO. A 
CO filled balloon was used to maintain a constant CO atmosphere and the reaction was 
heated to 70 °C using an oil bath for 9 hours. The reaction was then cooled to -40 °C and 
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MeOH (0.9 mL) and triphenylphosphine (2.2 mg, 0.009 mmol) were added prior to the 
addition of NaBH4 (6.4 mg, 0.17 mmol). After 20 minutes, the reaction was poured over 
water and extracted 2x with CH2Cl2. The aqueous layer was then acidified to a pH ~ 3 
with 10% aqueous HCl after which two more extractions were done using CH2Cl2. The 
combined organic layers were then washed with brine, dried using Na2SO4 and finally 
concentrated. Purification via silica gel chromatography (90:10, hexanes/EtOAc) yielded 
bicycle 3.10 (4.6 mg, 22%) as a colorless oil. Rf = 0.38 (80:20, hexanes/EtOAc). The 
NMR spectra matched previous reported data.20 
1
H NMR (400 MHz, CDCl3) δ 5.71 (ddd, J = 17.0, 10.1, 8.4 Hz, 1H), 5.30 – 5.28 (m, 
1H), 5.18 – 5.03 (m, 2H), 3.78 (dt, Jd = 9.4, Jt = 7.1 Hz, 1H), 3.65 (s, 3H), 3.05 – 2.97 (m, 
1H), 2.48 – 2.38 (m, 1H), 2.36 – 2.27 (m, 4H), 2.06 – 2.00 (m, 3H), 2.00 – 1.91 (m, 1H), 
1.71 – 1.58 (m, 2H), 1.49 – 1.40 (m, 2H), 1.34 – 1.27 (m, 1H) ppm. 
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4.2.2 General Procedure A for Cross Metathesis of Isocarbacyclin and Derivatives,  
3.14, 3.46 – 3.49
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In a glove box, Hoveyda-Grubbs II catalyst (10 mol %) was quickly added to a 
microwave vial.  The vial was sealed prior to removal from the glove box. To another 
vial, bicycle 3.10 (1 eq) and alkene (20 eq) were added and the vial was sealed, purged 
with N2 and dissolved in degassed CH2Cl2 (0.1 M). The catalyst was dissolved in 0.1 mL 
of CH2Cl2 and added to the mixture. The reaction was covered with foil and left stirring 
at room temperature overnight. The mixture was concentrated and purified via silica gel  
chromatography to afford the cross metathesis products.  
 
(15S)-acetoxy bicycle, 3.45 and dia-3.14 
The crude product was purified via silica gel chromatography (85:15, 
hexanes/EtOAc) yielded two diastereomers separately, 3.14 and dia-3.14. The 
diastereomeric ratio is 1:1 with diastereomer dia-3.14 eluting early. 
Diastereomer dia-3.14: Colorless oil (3.00 mg, 20%), Rf = 0.35 (75:25, hexanes/EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 5.61 – 5.48 (m, 2H), 5.29 – 5.28 (m, 1H), 5.26 – 5.21 (m, 
1H), 3.76 (dt, Jd = 10.9 Hz, Jt = 7.9 Hz, 1H), 3.67 (s, 3H), 3.04 – 2.98 (m, 1H), 2.47 – 
2.40 (m, 1H), 2.37 – 2.25 (m, 4H), 2.06 – 2.00 (m, 6H), 1.97 – 1.90 (m, 1H), 1.66 – 1.53 
(m, 4H), 1.49 – 1.41 (m, 2H), 1.34 – 1.27 (m, 7H), 0.89 – 0.86 (m, 3H) ppm. 
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13
C NMR (100 MHz, CDCl3): δ 174.3, 170.6, 141.7, 134.4, 130.6, 128.4, 74.8, 58.2, 
51.7, 45.9, 44.4, 40.0, 39.8, 34.6, 34.1, 31.7, 30.7, 29.9, 27.3, 25.0, 24.8, 22.7, 21.6, 14.2 
ppm. 
HRMS (ESI) calcd. for [C24H38O5+H-C2H4O2-H2O]
+: 329.2481, found: 329.2472.
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Diastereomer 3.14: Colorless oil, (2.80 mg, 19%), Rf = 0.25 (75:25, hexanes/EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 5.61 – 5.45 (m, 2H), 5.30 – 5.28 (m, 1H), 5.22 – 5.17 (m, 
1H), 3.78 (q, J = 8.8 Hz, 1H), 3.67 (s, 3H), 3.04 – 2.97 (m, 1H), 2.45 – 2.39 (m, 1H), 2.34 
– 2.26 (m, 4H), 2.06 – 1.99 (m, 5H), 1.96 – 1.89 (m, 2H), 1.71 – 1.54 (m, 4H), 1.50 – 
1.40 (m, 2H), 1.38 – 1.26 (m, 7H), 0.94 – 0.82 (m, 3H) ppm. 
13
C NMR (126 MHz, CDCl3) δ 174.3, 170.7, 141.6, 134.8, 130.8, 128.4, 75.1, 58.3, 51.7, 
45.8, 44.4, 39.8, 39.6, 34.6, 34.1, 31.6, 30.7, 29.9, 27.3, 25.0, 24.8, 22.7, 21.6, 14.1 ppm. 
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HRMS (ESI) calcd. for [C24H38O5+H-C2H4O2-H2O]
+: 329.2481, found: 329.2472.
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Methyl 2-((3aS,5R,6R,6aS)-5-hydroxy-6-((E)-oct-1-en-1-yl)-1,3a,4,5,6,6a- 
hexahydropentalen-2-yl)acetate, 3.46 
The crude product was purified via silica gel chromatography (90:10, 
hexanes/EtOAc) to yield ester 3.46 (5.0 mg, 90%) as a colorless oil. Rf = 0.38 (80:20, 
hexanes/EtOAc). 
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1
H NMR (400 MHz, CDCl3) δ 5.53 (dt, Jd = 14.1, Jt = 6.7 Hz, 1H), 5.31 – 5.25 (m, 2H), 
3.72 (dt, Jd = 9.5, Jt = 6.9 Hz, 1H), 3.67 (s, 3H), 3.01 – 2.96 (m, 1H), 2.35 – 2.44 (m, 1H), 
2.32 – 2.24 (m, 4H), 2.06 – 1.97 (m, 4H), 1.85 (q, J = 9.3 Hz, 1H), 1.66 – 1.58 (m, 6H), 
1.49 – 1.42 (m, 2H), 1.37 – 1.23 (m, 6H), 0.90  – 0.86 (m, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 174.4, 141.6, 133.5, 131.1, 128.4, 58.8, 51.7, 45.7, 44.5, 
39.8, 39.5, 34.1, 32.9, 31.8, 30.7, 29.9, 29.6, 29.0, 27.3, 24.8, 22.8, 14.3 ppm. 
HRMS (ESI) calcd. for [C22H36O3+H]
+: 349.2737, found: 349.2726. 
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Methyl 2-((3aS,6R,6R,6aS)-6-((E)-dodec-1-en-1-yl)-5-hydroxy-1,3a,4,5,6,6a- 
hexahydropentalen-2-yl)actate, 3.48 
The crude product was purified via silica gel chromatography (92:8, 
hexanes/EtOAc) to yield ester 3.48 (3.3 mg, 60%) as a yellow oil. Rf = 0.61 (80:20, 
hexanes/EtOAc). 
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1
H NMR (400 MHz, CDCl3) δ  5.53 (dt, Jd = 14.1, Jt = 6.7 Hz, 1H), 5.31 – 5.25 (m, 2H), 
3.72 (dt, Jd = 9.4, Jt = 6.7 Hz, 1H), 3.67 (s, 3H), 3.02 – 2.95 (m, 1H), 2.44 – 2.37 (m, 1H), 
2.35 – 2.25 (m, 4H), 2.06 – 1.97 (m, 5H), 1.85 (q, J = 9.2 Hz, 1H), 1.66 – 1.58 (m, 2H), 
1.45 (quint, J = 7.7 Hz, 2H), 1.38 – 1.26 (m, 18H), 0.88 (t, J = 6.6 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 174.2, 141.4, 133.4, 131.0, 128.3, 58.7, 51.5, 45.5, 44.4, 
39.6, 39.9, 33.9, 32.7, 31.9, 30.6, 29.9, 29.7, 29.6, 29.5, 29.5, 29.4, 29.2, 27.2, 24.7, 22.7, 
14.2 ppm. 
HRMS (ESI) calcd. for [C26H45O3+H]
+: 405.3363, found: 405.3357. 
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Methyl 2-((3aS,5R,6R,6aS)-5-hydroxy-6-((E)-3-phenylprop-1-en-1-yl)-1,3a,4,5,6,6a- 
hexahydropentalen-2-yl)acetate, 3.49 
The crude product was purified via semi-preparative HPLC using a reverse phase 
C18 column (Gemini NX Gemini-NK 5μ C18 110A, 250×10, No. 641016-12). The 
column was perfused at a flow rate of 4.6 mL/min with 65% of (water, 0.1% formic acid) 
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and 35% of CH3CN over 30 minutes. Product 3.49 was eluted at 16 minutes (1.02 mg, 
36%) as a colorless oil. Rf = 0.38 (80:20, hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 7.32 – 7.27 (m, 2H), 7.22 – 7.18 (m, 3H), 5.71 (dt, Jd = 
15.5, Jt = 6.8 Hz, 1H), 5.42 (ddt, Jd = 15.1, 8.5, Jt = 1.6 Hz, 1H), 5.29 – 5.28 (m, 1H), 
3.77 (q, J = 8.8 Hz, 1H), 3.66 (s, 3H), 3.39 (d, J = 6.7 Hz, 2H), 3.04 – 2.96 (m, 1H), 2.46 
– 2.40 (m, 1H), 2.37 – 2.26 (m, 3H), 2.05 – 1.99 (m, 3H), 1.93 (q, J = 9.2 Hz, 1H), 1.67 – 
1.50 (m, 3H), 1.49 – 1.41 (m, 2H), 1.29 (ddd, J = 12.4, 9.6, 7.3 Hz, 1H) ppm.  
13
C NMR (125 MHz, CDCl3) δ 174.3, 141.6, 140.8, 133.0, 131.5, 128.6 (2C), 128.6  
(2C), 128.4, 126.1, 58.7, 51.7, 45.8, 44.5, 39.9, 39.7, 39.3, 34.1, 31.7, 30.7, 27.3, 24.8 
ppm. 
HRMS (ESI) calcd. for [C23H30O3+H]
+: 355.2268, found: 355.2276. 
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methyl 2-((3aS,5R,6R,6aS)-5-hydroxy-6-((E)-pent-1-en-1-yl)-1,3a,4,5,6,6a- 
hexahydropentalen-2-yl)acetate, 3.47 
The crude product was purified via silica gel chromatography (90:10, 
hexanes/EtOAc) to yield ester 3.47 (3.4 mg, 55%) as a colorless oil. Rf = 0.61 (80:20, 
hexanes/EtOAc). 
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1
H NMR (400 MHz, CDCl3) δ 5.58 – 5.49 (m, 1H), 5.31 – 5.25 (m, 2H), 3.72 (td, Jd = 
9.4, Jt = 6.8 Hz, 1H), 3.67 (s, 3H), 2.99 (q, J = 8.9, 7.8 Hz, 1H), 2.44 – 2.36 (m, 1H), 2.36 
– 2.23 (m, 4H), 2.07 – 1.97 (m, 4H), 1.85 (q, J = 9.3 Hz, 1H), 1.66 – 1.58 (m, 5H), 1.49 – 
1.37 (m, 3H), 1.34 – 1.26 (m, 1H), 0.90 (t, J = 7.3 Hz, 3H) ppm. 
13
C NMR (176 MHz, CDCl3) δ 174.3, 141.6, 133.1, 131.4, 128.5, 58.9, 51.6, 45.7, 44.6, 
39.8, 39.6, 34.9, 34.1, 30.8, 29.9, 27.4, 24.9, 22.8, 13.8 ppm. 
HRMS (ESI) calcd. for [C19H30O3+H]
+: 307.2268, found: 307.2263. 
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4.2.3 Enzymetic Resolution of 1-octen-3-ol, 3.50 
 
 
(S)-3-acetoxy-1-octene, 3.13 
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To a stirred solution of racemic 1-octen-3-ol 3.50 (2.0 mL, 13 mmol) in vinyl 
acetate (22 mL) was added lipase (Novozyme® 435, 430 mg). After four hours of stirring, 
the enzyme was filtered off and washed with diethyl ether. The solution was then 
concentrated and purified via silica gel chromatography (95:5, hexanes/EtOAc) to yield 
acetate 3.13 (0.80 g, 37%, 99% ee) as a colorless liquid.42 The enantiomeric excesses 
were determined using chiral GC analysis. More details are provided in the supplemental 
information of our previous work.20  
1
H NMR (400 MHz, CDCl3) δ 5.77 (ddd, J = 17.0, 10.5, 6.4 Hz, 1H), 5.24 – 5.14 (m, 
2H), 5.15 (dt, Jd = 10.1, Jt = 1.1 Hz, 1H), 2.06 (s, 3H), 1.63 – 1.51 (m, 2H), 1.35 – 1.24  
(m, 6H), 0.89 – 0.86 (m, 3H) ppm. 
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4.2.4 General Procedure B for hydrolysis of Analogues, 3.2, 3.15 – 3.19 
 
A 10% NaOH aqueous solution (0.1 M) was added to an analogue methyl ester (1 
eq) in MeOH (0.1 M) at 0 °C. The reaction mixture was left to warm to room temperature 
overnight. The reaction was acidified to pH ~ 2-3 with 10% aqueous HCl, extracted 3x  
with CH2Cl2, dried over Na2SO4 and concentrated to give the final analogue. 
 
2-((3aS,5R,6R,6aS)-5-hydroxy-6-vinyl-1,3a,4,5,6,6a-hexahydropentalen-2-yl)acetic  
acid, 3.19 
The hydrolysis yielded analogue 3.19 (3.20 mg, 94%) as a colorless solid. Rf = 
0.27 (50:50, hexanes/EtOAc).  
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1
H NMR (400 MHz, CDCl3) δ 5.72 (ddd, J = 17.0, 10.1, 8.4 Hz, 1H), 5.31 – 5.29 (m, 
1H), 5.16 – 6.08 (m, 2H), 3.80 (dt, Jd = 9.5, Jt = 7.0 Hz, 1H), 3.03 – 3.00 (m, 1H), 2.47 – 
2.28 (m, 4H), 2.08 – 1.98 (m, 3H), 1.95 (q, J = 9.2 Hz, 1H), 1.67 – 1.60 (m, 2H), 1.53 – 
1.45 (m, 2H), 1.35 – 1.27 (m, 2H) ppm. 
13
C NMR (125 MHz, CDCl3) δ 178.5, 141.5, 139.9, 128.4, 116.8, 59.8, 45.8, 44.2, 39.8, 
39.7, 33.7, 30.6, 29.9, 27.1, 24.5 ppm. 
HRMS (ESI) calcd. for [C15H22O3-H]
-: 249.1491, found: 249.1492. 
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2-((3aR,5S,6S,6aR)-5-hydroxy-6-((S,E)-3-hydroxyoct-1-en-1-yl)-1,3a,4,5,6,6a- 
hexahydropentalen-2-yl)acetic acid, dia-3.2 
The hydrolysis yielded acid dia-3.2 (1.52 mg, 65%) as a colorless solid. Rf = 0.15 
(40:60, hexanes/EtOAc). 
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1
H NMR (400 MHz, CDCl3) δ 5.64 – 5.52 (m, 2H), 5.30 – 5.29 (m, 1H), 5.23 (q, J = 6.5 
Hz, 1H), 3.78 (dt, Jd = 9.5, Jt = 7.1 Hz, 1H), 3.04 – 2.98 (m, 1H), 2.44 – 2.18 (m, 6H), 
2.08 – 1.98 (m, 2H), 1.98 – 1.91 (m, 2H), 1.67 – 1.57 (m, 4H), 1.57 – 1.45 (m, 2H), 1.36 
– 1.26 (m, 6H), 0.90 – 0.86 (m, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 176.6, 141.5, 135.6, 132.3, 128.7, 73.0, 58.1, 45.8, 44.5, 
39.7, 39.67, 37.5, 33.5, 31.9, 30.6, 29.8, 27.1, 25.4, 24.5, 22.8, 14.2 ppm. 
HRMS (ESI) calcd. for [C21H34O4-H]
-: 349.2379, found: 349.2375. 
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Isocarbacyclin, 3.2 
The hydrolysis yielded isocarbacyclin 3.2 (1.50 mg, 68%) as a colorless solid. Rf 
= 0.15 (40:60, hexanes/EtOAc). 1H and 13C NMR are consistent with literature 
reports.24,25 
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1
H NMR (400 MHz, CDCl3) δ 5.59 – 5.46 (m, 2H), 5.30 – 5.29 (m, 1H), 4.06 (q, J = 6.7 
Hz, 1H), 3.80 – 3.73 (m, 1H), 3.03 – 2.96 (m, 1H), 2.44 – 2.20 (m, 6H), 2.10 – 1.88 (m, 
5H), 1.72 – 1.55 (m, 3H), 1.53 – 1.43 (m, 2H), 1.38 – 1.26 (m, 6H), 0.90 – 0.84 (m, 3H) 
ppm. 
13
C NMR (125 MHz, CDCl3) δ 177.6, 141.2, 135.8, 133.0, 129.1, 73.45, 58.1, 45.7, 44.5,  
39.6, 39.2, 37.2, 33.8, 31.8, 30.4, 29.9, 27.0, 25.4, 24.4, 22.8, 14.2 ppm. 
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Deoxy-isocarbacyclin, 3.15 
The hydrolysis yielded deoxy-isocarbacyclin 3.15 (1.68 mg, 83%) as a colorless 
solid. Rf = 0.23 (70:30, hexanes/EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 5.54 (dt, Jd = 15.4, Jt = 6.7 Hz, 1H), 5.31 – 5.24 (m, 2H), 
3.72 (dt, Jd = 9.6, Jt = 7.0 Hz, 1H), 3.02 – 2.95 (m, 1H), 2.44 – 2.35 (m, 3H), 2.33 – 2.20 
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(m, 2H), 2.07 – 1.98 (m, 5H), 1.85 (q, J = 9.3 Hz, 1H), 1.64 (dt, Jd = 15.1, Jt = 7.2 Hz, 
2H), 1.52 – 1.45 (m, 2H), 1.38 – 1.21 (m, 9H), 0.90 – 0.86 (m, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 177.8, 141.5, 133.5, 131.1, 128.5, 77.3, 58.8, 45.7, 44.5, 
39.8, 39.5, 33.6, 32.9, 31.8, 30.7, 29.6, 29.0, 27.2, 24.6, 22.8, 14.3 ppm. 
HRMS (ESI) calcd. for [C21H34O3-H]
-: 333.2430, found: 333.2434. 
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2-((3aS,5R,6R,6aS)-6-((E)-dodec-1-en-1-yl)-5-hydroxy-1,3a,4,5,6,6a 
-hexahydropentalen-2-yl)acetic acid, 3.17 
The hydrolysis yielded analogue 3.17 (2.02 mg, 90%) as a beige solid. Rf = 0.23 
(80:20, hexanes/EtOAc). 
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1
H NMR (400 MHz, CDCl3) δ 5.53 (dt, Jd = 14.1, Jt = 6.7 Hz, 1H), 5.34 – 5.24 (m, 2H), 
3.72 (dt, Jd = 9.5, Jt = 6.8 Hz, 1H),  3.01 – 2.96 (m, 1H), 2.44 – 2.20 (m, 5H), 2.07 – 1.97 
(m, 5H), 1.85 (q, J = 9.3 Hz, 1H), 1.67 – 1.60 (m, 2H), 1.52 – 1.45 (m, 2H), 1.38 – 1.25 
(m, 17H), 0.88 (t, J = 6.5 Hz, 3H) ppm. 
13
C NMR (176 MHz, CDCl3) δ 178.3, 141.5, 133.5, 131.2, 128.6, 58.8, 45.8, 44.6, 39.9, 
39.6, 33.4, 32.9, 32.1, 30.7, 29.8, 29.8, 29.8, 29.7, 29.7, 29.5, 29.4, 27.2, 24.6, 22.9, 14.29 
ppm. 
HRMS (ESI) calcd. for [C25H42O3-H]
-: 391.3056, found: 391.3063. 
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2-((3aS,5R,6R,6aS)-5-hydroxy-6-((E)-3-phenylprop-1-en-1-yl)-1,3a,4,5,6,6a- 
hexahydropentalen-2-yl)acetic acid, 3.18 
The hydrolysis yielded analogue 3.18 (0.80 mg, 84%) as a colorless solid. Rf = 
0.36 (50:50, hexanes/EtOAc). 
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1
H NMR (400 MHz, CDCl3) δ 7.29 (dd, J = 8.5, 6.7 Hz, 2H), 7.22 – 7.16 (m, 3H), 5.70 
(dt, Jd = 15.4, Jt = 6.8 Hz, 1H), 5.73 – 5.66 (ddt, Jd = 15.5, 8.6, Jt = 1.4 Hz, 1H), 5.28 – 
5.27 (m, 1H), 3.76 (td, Jd = 9.5, Jt = 7.0 Hz, 1H), 3.38 (d, J = 6.7 Hz, 2H), 3.03 – 2.95 (m, 
1H), 2.52 – 2.45 (m, 5H), 2.05 – 1.98 (m, 3H), 1.92 (q, J = 9.2 Hz, 1H), 1.65 – 1.43 (m, 
3H), 1.31 – 1.26 (m, 2H) ppm. 
13
C NMR (176 MHz, CDCl3) δ 176.5, 141.4, 140.6, 132.8, 131.28, 128.4 (4C), 128.4, 
126.0, 58.5, 45.6, 44.4, 39.7, 39.5, 39.1, 33.2, 30.5, 29.7, 27.0, 24.4. 
HRMS (ESI) calcd. for [C22H28O3-H]
-: 339.1960, found: 339.1967. 
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4.3 Synthesis of Tricyclic Core (3.30) in the Model System 
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Methyl 2-((methylsulfonyl)oxy)cyclopent-1-enecarboxylate, 3.26 
Following a previously reported procedure, mesylate 3.26 was synthesized as a 
brown oil (434 mg, 40% yield). Rf = 0.29 (70:30, hexanes/EtOAc). 
1H and 13C NMR are 
consistent with literature reports.39 
1
H NMR (500 MHz, CDCl3) δ 3.74 (s, 3H), 3.25 (s, 3H), 2.80 (tt, J = 8.0, 2.7 Hz, 1H),  
2.64 (tt, J = 7.7, 2.6 Hz, 2H) 1.97 (quint, J = 7.8 Hz, 2H) ppm. 
  
114 
 
 
Methyl 2-vinylcyclopent-1-ene-1-carboxylate, 3.27 
To a solution of LiBr (356 mg, 4.1 mmol) and Pd(PPh3)4 (316 mg, 0.27 mmol) in 
THF (17 mL) was added a solution of mesylate 3.26 (600 mg, 2.7 mmol) and 
vinyltributylstannane (1.6 mL, 5.9 mmol) in THF (10 mL) under an atmosphere of N2. 
The solution was heated in a microwave reactor at 90 °C for 24 hours, cooled to room 
temperature, diluted with CH2Cl2 and washed with water. The aqueous layer was back 
extracted with CH2Cl2, and the combined organic layers were washed with 10% NH4OH 
solution, water and saturated aqueous NaCl, dried over Na2SO4 and concentrated. 
Purification via silica gel chromatography (97:2, hexanes/diethyl ether) yielded ester 3.27 
(250 mg, 60%) as a colorless oil. Rf = 0.52 (90:10, hexanes/EtOAc). 
1H and 13C NMR are 
consistent with literature reports.43 
1
H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 17.6, 10.8 Hz, 1H), 5.44 – 5.38 (m, 2H), 
3.74 (s, 3H), 2.72 – 2.65 (m, 4H), 1.86 (quint, J = 7.6 Hz, 2H) ppm. 
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2-Ethenyl-1-cyclopentenecarboxylic Acid, 3.28 
Following a previously reported procedure, acid 3.28 was synthesized as an off-
white solid (38 mg, 83% yield). Rf = 0.90 (89:10:1, hexanes/EtOAc/AcOH). 
1H and 13C 
NMR are consistent with literature reports.41,43 
1
H NMR (400 MHz, CDCl3) δ 12.24 (bs, 1H), 7.56 (dd, J = 17.6, 10.8 Hz, 1H), 5.47 (dt, 
Jd = 17.6 Hz, Jt = 0.6 Hz, 1H), 5.44 (d, J = 10.8 Hz, 1H), dtd (Jd = 9.8, 1.6, Jt = 7.8, 4H),  
1.89 (quint, J = 7.7 Hz, 2H) ppm. 
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(E,Z)-1(penta-2,4-dien-1-yl)-2-vinylcyclopent-1-ene, 3.29   
A microwave vial with dienoic acid 3.29 (16 mg, 0.12 mmol), pentadienyl 
substrate 1,4-pentadien-3-ol 3.4 (13 µL, 0.14 mmol) and water (2.5 µL, 0.14 mmol) in 
CDCl3 (1.1 mL) was capped with a septum, and purged with N2. 
Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (5.9 mg, 0.0057 mmol) and 
PPh3 (6.0 mg, 0.023 mmol) were dissolved in  CDCl3 (0.1 mL) and added to the mixture. 
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The mixture was left at room temperature under a balloon of N2 for 48 hours. The 
solution was concentrated and purified via silica gel chromatography (pentane) to yield 
tetraene 3.29 (15 mg, 74% yield) as a colorless oil. Rf (mixture of diastereomers) = 0.91 
(hexanes).  The product is a mixture of two diastereomers in a 1.85:1 ratio. 
Mixture of two inseparable diastereomers  
Diastereomer A (major): 
1
H NMR (500 MHz, CDCl3) δ 6.74 – 6.64 (m, 2H) 6.07 – 6.02 (m, 2H), 5.42 – 5.37 (m, 
1H), 5.15 – 5.13 (m, 1H), 5.09 – 5.05 (m, 2H), 3.11 (d, J = 7.7 Hz, 2H), 2.47 – 2.51 (m, 
2H), 2.40 – 2.43 (m, 2H), 1.79 – 1.86 (m, 2H) ppm. 
Diastereomer B (minor): 
1
H NMR (500 MHz, CDCl3) δ 6.74 – 6.64 (m, 1H), 6.30 (dt, Jd = 17.0, Jt = 10.3 Hz, 1H), 
5.68 - 5.62 (m, 1H), 5.42 – 5.37 (m, 1H), 5.24 – 5.20 (m, 2H), 5.15 – 5.13 (m, 1H), 4.97 – 
4.99 (m, 1H), 2.99 (d, J = 7.1 Hz, 2H), 2.47 – 2.51 (m, 2H), 2.40 – 2.43 (m, 2H), 1.79 – 
1.86 (m, 2H) ppm. 
13
C NMR (125 MHz, CDCl3) δ 140.4, 140.1, 137.1, 135.1, 134.7, 132.1, 132.0, 131.9, 
130.9, 130.8, 130.0, 129.3, 117.7, 115.5, 113.5, 113.5, 37.1, 36.9, 32.5, 32.5, 31.8, 27.2, 
21.5, 21.5. ppm. 
HRMS (APPI) calcd. for [C12H16]
+: 161.1330, found: 161.1323. 
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(1R,2R,3aS,7aS)-1-vinyl-2,3,3a,4,5,6,7,7a-octahydro-1H-cyclopenta[a]pentalen-2-ol, 
3.30 
To a solution of tetraene 3.29 (2.5 mg, 0.013 mmol) in 1,2-dichloroethane (0.1 
mL) were added [RhCl(CO)2]2 (1.0 mg, 0.0026 mmol) and AgSbF6 (0.45 mg, 0.0013 
mmol) before purging thoroughly with CO. A CO filled balloon was used to maintain a 
constant CO atmosphere and the reaction was heated to 80 °C using an oil bath for 14 
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hours. The reaction was then cooled to -40 °C and MeOH (0.1 mL) and 
triphenylphosphine (0.34 mg, 0.0013 mmol) were added prior to the addition of NaBH4 
(1.0 mg, 0.027 mmol). After 20 minutes, the reaction was poured over water and 
extracted 2x with CH2Cl2. The aqueous layer was then acidified to a pH ~ 3 by the 
addition of a 10% aqueous HCl after which two more extractions were done using 
CH2Cl2. The combined organic layers were then washed with brine, dried using Na2SO4 
and concentrated to yield tricycle 3.30 and other isomerized products. Tricycle 3.30 was 
not fully characterized due to isomerization. 
4.4 Synthesis of Tetraene 3.42 in the Real System 
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tert-butyl 2-(2-oxocyclopentyl)acetate, 3.37 
To a stirred solution of LiHMDS (4.7 g, 28 mmol) in THF (170 mL) at -78 °C, 
was added slowly a solution of cyclopentanone 3.35 (2.5 mL, 28 mmol) in THF (30 mL). 
After an hour the reaction temperature was raised to -20 °C gradually over 30 minutes. 
The reaction temperature was lowered to -78 °C, and a solution of tert-butyl 
bromoacetate (5.0 mL, 34 mmol) in THF (30 mL) was added slowly and the reaction was 
left to warm gradually to room temperature. After stirring overnight, the reaction was 
quenched with saturated NH4Cl solution, and extracted 2x with diethyl ether. The 
combined organic layers were washed with water and brine subsequently, dried using 
Na2SO4 and concentrated. Purification via silica gel chromatography (95:5, 
hexanes/acetone) yielded ester 3.37 (4.0 g, 72% yield) as a colorless oil. Rf = 0.43 (90:10, 
hexanes/acetone).  
1
H NMR (400 MHz, CDCl3) δ 2.64 (dd, J = 15.8, 3.7 Hz, 1H), 2.46 – 2.24 (m, 4H), 2.22 
– 2.11 (m, 1H), 2.04 (dddt, Jd = 12.4, 8.4, 6.3, Jt = 1.8 Hz, 1H), 1.79 (dddt, J = 11.7, 11.1, 
8.2, 6.3 Hz, 1H), 1.67 – 1.57 (m, 1H), 1.44 (s, 9H) ppm.  
13
C NMR (100 MHz, CDCl3) δ 219.6, 171.5, 80.9, 45.9, 37.7, 35.3, 29.4, 28.2 (3C), 20.8 
ppm. 
HRMS (ESI) calcd. for [C11H18O3+Na]
+: 221.1148, found: 221.1149. 
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Methyl 3-(2-(tert-butoxy)-2-oxoxyxlopentane-1-carboxylate, 3.38 
To a stirred solution of LiHMDS (4.2 g, 25 mmol) in THF (70 mL) at -78 °C, was 
added slowly a solution of tert-butyl 2-(2-oxocyclopentyl)acetate 3.37 (2.5 g, 13 mmol) 
in THF (26 mL). After an hour stirring a solution of methyl chloroformate (1.9 mL, 25 
mmol) in THF (26 mL) was added slowly. After stirring for four hours at the same 
temperature the reaction turned from dark yellow to bright orange. The reaction was 
quenched with a saturated NH4Cl solution, and extracted 3x with CH2Cl2. The organic 
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layers were washed with water and brine subsequently, dried using Na2SO4 and 
concentrated. Purification via silica gel chromatography (90:10, hexanes/acetone) yielded 
diester 3.38 (2.5 g, 70%) as a rusty pink oil. Two isomers are produced, diastereomers A 
and B. The diastereomeric ratio is 2.5:1.0 with diastereomer A eluting early. 
Diastereomer A: 
1
H NMR (400 MHz, CDCl3) δ 3.73 (s, 3H), 3.34 (dd, J = 9.3, 3.8 Hz, 1H), 2.68 – 2.59 
(m, 1H), 2.53 – 2.45 (m, 1H), 2.37 – 2.15 (m, 4H), 1.69 – 1.57 (m, 1H), 1.43 (s, 9H) ppm. 
Rf = 0.32 (90:10, hexanes/acetone). 
Diastereomer B:  
1
H NMR (400 MHz, CDCl3) δ 3.75 (s, 3H), 3.28 (dd, J = 11.5, 8.5 Hz, 1H), 2.68 – 2.59 
(m, 1H), 2.53 – 2.45 (m, 2H), 2.42 – 2.36 (m, 2H), 2.10 – 2.02 (m, 1H), 1.82 (dtd, Jd = 
12.7, Jt = 10.3, Jd = 7.2 Hz, 1H), 1.43 (s, 9H) ppm. Rf = 0.27 (90:10, hexanes/acetone).  
13
C NMR (100 MHz, CDCl3) δ 211.7 (2C), 1.71.0, 170.7, 169.9, 169.4, 81.1, 81.0, 54.4, 
53.2, 52.6, 52.5, 45.7, 45.6, 35.7, 35.0, 28.1 (3C), 28.0 (3C), 27.8, 26.7, 25.1, 24.7 ppm. 
HRMS (ESI) calcd. for [C13H20O5+H]
+: 257.1384, found: 257.1389. 
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Methyl 3-(2-tert-butoxy)-2-oxoethyl)-2-((methylsulfonyl)oxy)cyclopent-1-ene-1- 
carboxylate, 3.39 
To a mixture of diester 3.38 (57 mg, 0.22 mmol) in DME (2.2 mL) at 0 °C were 
slowly added triethylamine (0.15 mL, 1.1 mmol) and mesyl chloride (0.04 mL, 0.57 
mmol). The reaction mixture was then allowed to warm to room temperature for 14 h, 
diluted with diethyl ether, and washed with water. The aqueous layer was back extracted 
2x with diethyl ether, and the organic layers were combined, washed with water and a 
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saturated NaCl solution. The solution was dried using Na2SO4 and concentrated to yield 
mesylate 3.39 as a brown oil. This β-mesyloxyenone decomposes on standing neat at 
room temperature for several hours. It was used in the subsequent Stille coupling without 
further purification immediately after formation. Rf = 0.62 (70:30, hexanes/EtOAc). 
Mesylate 3.39 was not fully characterized as a result of the formation of another  
unknown byproduct. 
 
Methyl 3-(2-(tert-butoxy)-2-oxoethyl)-2-vinylcyclopent-1-ene-1-carboxylate, 3.40 
To a solution of LiBr (661 mg, 7.6 mmol) and Pd(PPh3)4 (293 mg, 5 mol %) in 
THF (30 mL) was added a solution of  mesylate 3.39 (1.6 g, 5.0 mmol) and 
vinyltributylstannane (2.9 mL, 9.9 mmol) in THF (20 mL) under an atmosphere of N2. 
The solution was refluxed for 48 hours, cooled to room temperature, diluted with CH2Cl2 
and washed with water. The aqueous layer was back extracted 2x with CH2Cl2, and the 
combined organic layers were washed with 10% NH4OH aqueous solution (2x50 mL), 
water and saturated aqueous NaCl. The solution was dried using Na2SO4 and 
concentrated before purification via silica gel chromatography (98:2, hexanes/EtOAc) to 
give ester 3.40 (232 mg, 20% (over 2 steps)) as a yellow oil. Rf = 0.58 (90:10, 
hexanes/EtOAc). 
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1
H NMR (400 MHz, CDCl3) δ 7.38 (dd, J = 17.9, 11.0 Hz, 1H), 5.52 – 5.43 (m, 2H), 
3.75 (s, 3H), 3.51 – 3.46 (m, 1H), 2.75 – 2.61 (m, 2H), 2.50 (dd, J = 15.3, 3.0 Hz, 1H), 
2.11 (dd, J = 15.4, 11.1 Hz, 1H), 2.01 (dq, Jd = 13.2, Jq = 9.3 Hz, 1H), 1.73 (ddt, Jd = 
13.3, 7.6, Jt = 2.0 Hz, 1H), 1.46 (s, 9H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 172.0, 166.2, 153.8, 130.3, 130.1, 120.9, 80.7, 51.4, 42.4, 
38.9, 32.0, 28.2 (3C), 27.9 ppm.  
HRMS (APPI) calcd. for [C15H22O4+Na]
+: 289.1410, found: 289.1410. 
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3-(2-(tert-butoxy)-2-oxyethy)-2-vinylcyclopent-1-ene-1-carboxylic acid, 3.41 
LiOH (0.05 mL, 10% in 1:1, MeOH:H2O) was added to dienoate 3.40 (3.2 mg, 
0.013 mmol) in THF (0.1 mL) at 0 °C. The mixture was left to warm to room temperature 
for 12 hours and turned from colorless to brown. The mixture was acidified with 10% 
aqueous HCl until pH ~ 2, extracted 3x with diethyl ether, dried over Na2SO4, and 
concentrated to give dienoic acid 3.41 (2.4 mg, 80%) as an off-white solid. Rf = 0.27 
(70:30, hexanes/EtOAc, large streak). 
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1
H NMR (500 MHz, CDCl3) δ 10.47 (bs, 1H), 7.40 (dd, J = 17.8, 11.0 Hz, 1H), 5.56 – 
5.48 (m, 2H), 3.50 – 3.54 (m, 1H), 2.79 – 2.65 (m, 2H), 2.51 (dd, J = 15.4, 2.9 Hz, 1H), 
2.16 (dd, J = 15.4, 11.1 Hz, 1H), 2.04 (dq, Jd = 13.1, Jq = 9.2 Hz, 1H), 1.76 (ddt, Jd = 
13.0, 7.6, Jt = 2.0 Hz, 1H), 1.46 (s, 9H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 172.1, 166.2, 153.9, 130.3, 130.1, 120.9, 80.7, 51.5, 42.5, 
38.9, 32.1, 28.2 (3C) ppm. 
HRMS (ESI) calcd. for [C14H20O4-H]
-: 251.1283, found: 251.1283. 
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(6E/Z,8E)-methyl 6-allylideneundeca-8,10-dienoate, 3.42 
A microwave vial with dienoic acid 3.41 (2.4 mg, 0.0097 mmol) and 1,4-
pentadien-3-ol 3.4 (1.2 µL, 0.012 mmol) in CH2Cl2 (0.1 M) was capped with a septum, 
purged with N2, tetrakis(triphenylphosphine) palladium (1.2 mg, 10 mol %) was added, 
and the vial was sealed and purged with N2. The mixture was left at room temperature 
under a balloon of N2 for 48 hours. The solution was concentrated and purified via silica 
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gel chromatography (98:2, hexanes/EtOAc) to yield tetraene 3.42 (1.4 mg, 53%) as a 
yellow oil. Two isomers are produced, diastereomers A and B. The diastereomeric ratio is 
3.0:1.0 with diastereomer A eluting early. 
Diastereomer A (major): 
1
H NMR (400 MHz, CDCl3) δ 6.72 – 6.63 (m, 1H), 6.58 – 6.47 (m, 1H), 6.07 – 6.01 (m, 
1H), 5.39 – 5.33 (m, 1H), 5.24 – 5.20 (m, 1H), 5.17 – 5.09 (m, 3H), 3.32 – 3.26 (m, 1H), 
3.07 (d, J = 7.7 Hz, 2H), 2.58 – 2.51 (m, 1H), 2.49 – 2.43 (m, 1H), 2.31 – 2.24 (m, 1H), 
2.03 – 1.92 (m, 2H), 1.71 – 1.65 (m, 1H), 1.45 (s, 9H) ppm. Rf = 0.67 (90:10, 
hexanes/EtOAc). 
Diastereomer B (minor): 
1
H NMR (400 MHz, CDCl3) δ 6.72 – 6.63 (m, 1H), 6.58 – 6.47 (m, 1H), 6.29 (dt, Jd = 
17.0, Jt = 10.3 Hz, 1H), 6.07 – 6.01 (m, 1H), 5.65 – 5.58 (m, 1H), 5.17 – 5.09 (m, 1H), 
4.99 (d, J = 10.4, 2H), 3.32 – 3.26 (m, 1H), 2.96 (dd, J = 7.5, 3.2 Hz, 2H), 2.58 – 2.51 (m, 
1H), 2.49 – 2.43 (m, 1H), 2.31 – 2.24 (m, 1H), 2.03 – 1.92 (m, 2H), 1.71 – 1.65 (m, 1H), 
1.45 (s, 9H) ppm. Rf = 0.60 (90:10, hexanes/EtOAc). 
13
C NMR (100 MHz, CDCl3) δ 172.9 (2C), 141.2, 140.7, 137.5, 137.1, 137.0, 132.1, 
131.9, 131.7, 130.2, 129.4, 129.3, 128.9, 117.9 (2C), 115.7, 114.0, 80.2 (2C), 41.8 (2C), 
39.2 (2C), 34.7, 34.6 (2C), 31.8, 28.3 (6C), 27.3 (2C) ppm. 
HRMS (ESI) calcd. for [C18H26O2+H]
+: 275.2006, found: 275.2003. 
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6a-ethyl-6-(penta-2,4-dien-1-yl)-3,5,6,6a-tetrahydro-2H-cyclopenta[b]furan-2-one,  
3.45 
To a solution of tetraene 3.42 (43 mg, 0.16 mmol) in 1,2-dichloroethane (2.1 mL) 
were added [RhCl(CO)2]2 (8.3 mg, 0.021 mmol) and AgSbF6 (4.9 mg, 0.016 mmol) 
before purging thoroughly with CO. A CO filled balloon was used to maintain a constant 
CO atmosphere and the reaction was left at room temperature for 14 hours. The solvent 
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was concentrated and the crude was purified via silica gel chromatography (80:20, 
hexanes/EtOAc) to yield compound 3.45 (8.8 mg, 24%) as a yellow oil. Rf = 0.36 (80:20, 
hexanes/EtOAc). Two isomers are produced, diastereomers A and B. The diastereomeric 
ratio is 4.0:1.0 with diastereomer B eluting early. Only isomer A was analyzed. 
1
H NMR (400 MHz, CDCl3) δ 6.59 (dt, Jd = 16.6, Jt = 10.6 Hz, 1H), 6.15 – 6.08 (m, 1H), 
5.58 – 5.51 (m, 2H), 5.26 – 5.12 (m, 2H), 2.96 – 2.85 (m, 3H), 2.82 (dddd, J = 10.4, 7.8, 
5.5, 2.1 Hz, 1H), 2.66 – 2.58 (m, 1H), 2.37 – 2.30 (m, 1H), 2.18 – 2.11 (m, 1H), 1.93 – 
1.77 (m, 2H), 0.89 – 0.84 (m, 3H) ppm. 
13
C NMR (101 MHz, CDCl3) δ 176.9, 142.3, 131.8, 130.9, 128.4, 128.1, 118.2, 101.9, 
39.5, 38.2, 38.1, 28.6, 24.8, 7.7 ppm. 
HRMS (ESI) calcd. for [C14H18O2+H]
+: 219.1385, found: 219.1380. 
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CHAPTER IV 
DECARBOXYLATIVE AND DEHYDRATIVE COUPLING OF DIENOIC ACIDS  
AND PENTADIENYL ALCOHOLS TO FORM 1,3,6,8-TETRAENES
 
Abu Deiab, G. I.; Al-Huniti, M. H.; Hyatt, I. F. D.; Nagy, E. E.; Gettys, K. E.; 
Sayed, S. S.; Joliat, C. M.; Daniel, P. E.; Vummalaneni, R. M.; Moorehead, A. Jr.;  
Sargent, A. L.; Croatt, M. P. Beilstein J. Org. Chem. (submitted). 
1. Background 
The construction of carbon-carbon bonds where the product is electronically 
neutral remains a difficult and important problem in organic synthesis. Cross-coupling 
reactions provide avenues to these otherwise difficult molecules, but often require 
prefunctionalization of the coupling partners.1-9 However, recent C-H activation research 
has enabled the use of further simplified starting materials.10-18 Another approach to the 
formation of C-C bonds is through decarboxylative coupling reactions. This can be 
arrived in a one component fashion via the removal of CO2 from an ester or in a two 
component manner by removal of CO2 from a carboxylic acid and coupling this to a 
substrate with a benzylic or allylic leaving group.
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Scheme 4.1. Prior and Current Decarboxylative Couplings. 
Typical decarboxylative coupling reactions utilize an allylic or benzylic ester with 
either an anion-stabilizing group adjacent to the carboxyl group (i.e. carbonyl,19-20 
nitrile,21-23 nitro,24-25 or alkyne,19, 26-30 Scheme 4.1), or use an aryl carboxylate31-32 which 
typically requires the assistance of silver or copper (I) salts for the decarboxylative step. 
It is rare to use a pentadienyl leaving group,33 or to have a diene or simple alkene 
adjacent to the carboxyl group.34-37 Despite the absence of this type of reactivity, the 
decarboxylative coupling of a pentadienyl dienoate (4.9; Scheme 4.2) was so desirable 
for our group’s synthesis of clinprost that we attempted the reaction.38-39 Fortunately, this 
coupling reaction was successfully employed in our reported nine-step synthesis of 
clinprost.39 A structurally related compound (4.11) reacted similarly, however, the 
sorbate derivative (4.13) was low yielding with the majority of the material only 
rearranging to the linear ester. In all three of these cases, we never observed the fully 
conjugated tetraene. 
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Scheme 4.2. Esters Examined in the Decarboxylation Reaction. 
It was determined that modifying the dienoate motif yielded only the rearranged 
product under the reaction conditions, including the dihydro (4.14), cinnamate (4.15), 
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benzoate (4.16), and acrylate (4.17) analogues (Scheme 4.2). Moreover, allylic dienoates 
4.18 and 4.19 gave no reaction with Pd(0) catalysis.  
These results led us to the determination that there was a unique reactivity imbued 
to the molecule by having both the dienoate and pentadienyl moieties. Herein, are 
presented more details for this reaction, including the substrate scope for the  
intermolecular case. 
2. Results and Discussion 
In addition to determining the requisite nature of both the pentadienyl and 
dienoate groups, it was found that trace amounts of water were required (Table 4.1). For 
example, careful exclusion of water from reagents and solvent and performing the 
reaction in the glovebox led to no reaction (entry 1). Less than 1 equivalent of water 
allowed for a slow reaction and incomplete conversion; 1-2 equivalents was optimal with 
yields around 70%, and more water was not beneficial (entries 2-8). The use of equimolar 
amounts of methanol and water as a protic source allowed for decarboxylation to take 
place but with a low yield (entry 9), and the reaction run in TFE as a solvent did not 
result in any decarboxylation (entry 10). 
 
 
 
 
 
150 
 
Table 4.1. Optimization of the One-Component Decarboxylation Reaction.a 
 
Entry Catalyst Solvent Additive 
Yield of 4.10 
(Yield of 4.22)
b 
1 Pd(PPh3)4 CH2Cl2 Anhydrous 0% (99%) 
2 Pd(PPh3)4 CH2Cl2 0.5 eq H2O 27% 
3 Pd(PPh3)4 CH2Cl2 1.1 eq H2O 77% 
4 Pd(PPh3)4 CH2Cl2 1.3 eq H2O 72% 
5 Pd(PPh3)4 CH2Cl2 
Silylated glass, 1 
eq H2O 
55% (15%) 
6 Pd(PPh3)4 CH2Cl2 Dry glass balls 37% (24%) 
7 Pd(PPh3)4 CH2Cl2 Wet glass balls 51% 
8 Pd(PPh3)4 CH2Cl2/H2O Biphasic 49% 
9 Pd(PPh3)4 CH2Cl2 
1eq MeOH, 1 eq 
H2O 
33% (26%) 
10 Pd(PPh3)4 TFE Trace CH2Cl2 0% 
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11 Pd2(dba)3 CH2Cl2 
0% PPh3, 1 eq 
H2O 
0% 
12 Pd2(dba)3 CH2Cl2 
10% PPh3, 1 eq 
H2O 
64% 
13 Pd2(dba)3 CH2Cl2 
20% PPh3, 1 eq 
H2O 
61% 
14 Pd2(dba)3 CH2Cl2 
30% PPh3, 1 eq 
H2O 
12% 
15 Pd2(dba)3 CH2Cl2 
10% L1, 1 eq 
H2O 
70% 
16 Pd2(dba)3 CH2Cl2 
10% L2, 1 eq 
H2O 
70% 
17 Pd2(dba)3 CH2Cl2 
10% L4, 1 eq 
H2O 
18% 
18 Pd2(dba)3 CH2Cl2 
10% L5, 1 eq 
H2O 
10% 
19 Pd(OAc)2 CH2Cl2 1 eq H2O 0% 
20 Pd(OAc)2 CH2Cl2 
40% PPh3, 1 eq 
H2O 
10% 
21 none CH2Cl2 
1 eq PPh3, 1 eq 
H2O 
0% 
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aReaction Conditions: Pd metal (10 mol %) and the indicated solvent and additives for 24  
hours.  bIsolated yields. 
In addition to the requirement for water, it was determined that phosphine ligands 
were necessary (entry 11), either as ligands or as participants in the reaction as discussed 
later. The typical catalyst used, Pd(PPh3)4, worked well; however, it was found that a 
more ideal ratio of palladium metal to ligand was 1:1 or 1:2, with greater amounts of 
triphenylphosphine stopping the reaction when using the Pd2dba3 catalyst (entries 12-14). 
It was determined that reactions performed in the presence of electron-rich ligands had 
both quicker kinetics and more efficient yields (entries 15-18 and Supporting Information 
for kinetic information). Although not as efficient, it was found that a palladium(II) 
catalyst functioned in this reaction, presumably functioning as a pre-catalyst and being 
reduced in situ to the palladium(0) catalyst (entries 19 and 20). As a control reaction, it 
was found that no reaction occurred in the absence of palladium catalyst (entry 21). 
As shown earlier, bis-allylic sorbate (4.13; Scheme 4.2) was found to be low 
yielding for the decarboxylative coupling reaction. Reactions of sorbate 4.13 monitored 
by 1H NMR showed nearly quantitative isomerization of the bis-allylic group into a linear 
pentadienyl system. Increasing the reaction time did not result in greater conversion to 
tetraene 4.8a, which indicates that the products may be competitively ligating and 
poisoning the Pd(0)-catalyst. The isomerization reaction was presumably occurring via 
ionization of the allylic system using Pd(0), followed by recombination of the 
carboxylate at the terminal position of the pentadienyl system. Based on these data, we 
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hypothesized that a two component reaction using a dienoic acid and bis-allylic acetate 
might be possible, however, the presence of both water and a carboxylic acid would 
increase the possibility for isomerization of the 1,3,6,8-tetraenes into the fully conjugated 
1,3,5,7-tetraenes, or possibly polymerization. 
Despite the low yield for decarboxylation with sorbate 4.13, the initial attempt 
used inexpensive sorbic acid as the dienoic acid. Gratifyingly, this reaction was 
successful and it was again determined that no isomerization to the fully conjugated 
system was observed (Table 4.2, entry 1). Other bis-allylic leaving groups were studied 
and, unexpectedly, it was determined that divinylcarbinol was superior (entries 1-6). In 
fact, the better leaving groups were either slow or ineffective. This could be due to the 
less basic leaving groups not sufficiently deprotonating sorbic acid, which may be 
required for this reaction as is discussed mechanistically later (Scheme 4.3). Similar to 
the single component reaction, more than two equivalents of phosphine, relative to 
palladium metal, was detrimental (compare entries 12-14 of Table 4.1 with entries 6-8 of 
Table 4.2), however, the reaction was successful using Pd(PPh3)4 (entry 9). 
Table 4.2. Optimization of the Two-Component Decarboxylation Reaction.a 
 
Entry
 
Pentadienyl Group Additive Yield
b 
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1 4.6a, X = OAc PPh3 (20 mol %) 12% 
2 4.6b, X = OCO2Me PPh3 (20 mol %) 35% 
3 4.6c, X = OBz PPh3 (20 mol %) 11% 
4 4.6d, X = O2C(4-CF3Ph) PPh3 (20 mol %) 6% 
5 4.7a, X = Br PPh3 (20 mol %) 0% 
6 4.6e, X = OH PPh3 (20 mol %) 40% 
7 4.6e, X = OH PPh3 (10 mol %) 18% 
8 4.6e, X = OH PPh3 (30 mol %) 24% 
9c 4.6e, X = OH NA 28% 
aReaction Conditions: Sorbic acid (4.5a, 1 eq), pentadienyl group (4.6 or 4.7, 1 eq), 
Pd2(dba)3•CHCl3 (5 mol %) unless indicated otherwise, H2O (1 eq), in CDCl3 for 48  
hours. bNMR yields. cPd(PPh3)4 (10 mol %). 
To further understand this interesting decarboxylative coupling reaction, a handful 
of different pentadienyl groups and dienoic acids were examined (Table 4.3). It was 
found that both a methyl or phenyl substituent on the alcohol derivative would result in 
branched product 4.8b or 4.8d being the major product with approximately 10% of the 
product mixture being the linear product (entries 2-4). The yields for these reactions were 
low, but the remaining material was typically starting material and the ester where the 
acid and alcohol are coupled together. With these highly unsubstituted tetraene products, 
it is hypothesized that the product may be sequestering the palladium catalyst. Two cyclic 
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dienyl acetates were also studied (entries 5 and 6) and they yielded tetraenes 4.8f and 
4.8g. The dienes of entries 5 and 6 could have formed additional isomers by coupling to 
the other end of the pentadienyl group, but only one regioisomer was observed.  
Table 4.3. Substrate Scope for the Two-Component Decarboxylation Reaction.a 
 
Entry
 
Dienoic Acid Pentadienyl Group Yield (Product)
b 
1 
 
4.5a 
 
4.6e 
 
40% (4.8a) 
2 
 
4.5a 
 
4.7b 
 
2% (4.8b/4.8c) 
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3 
 
4.5a 
 
4.6f  
21%, 17%c (4.8d/4.8e) 
4 
 
4.5a 
 
4.6g  
13%, 6%c (4.8d/4.8e) 
5 
 
4.5a 
 
4.7c 
 
16%c (4.8f) 
6 
 
4.5a 
 
4.7d 
 
18%c (4.8g) 
7 
 
 
4.6e 
 
14% (4.8h/4.8i/4.8j) 
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4.5b 
8 
 
4.5c 
 
4.6e 
 
27% (4.8k) 
9 
 
4.5d 
 
4.6e 
 
36% (4.8l) 
10 
 
4.5e 
 
4.6e 
Decomposition 
11  
4.5f 
 
4.6e 
Decomposition 
12  
4.5g 
 
4.6e 
 
76% (4.8m) 
aReaction Conditions: Dienoic acid (4.5, 1 eq), pentadienyl group (4.6 or 4.7, 1 eq), H2O  
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(1 eq), Pd2(dba)3•CHCl3 (5 mol %), PPh3 (20 mol %), in CDCl3 for 48 hrs. bNMR yields.  
cIsolated yields.  
With respect to the dienoic acid, it was determined that the unsubstituted 
compound, pentadienoic acid, underwent decarboxylative coupling, although as a mixture 
of E/E, E/Z, and Z/Z isomers (entry 7). Alkyl- and aryl-substituents were possible on the 
dienoate with the exception of an aryl group at the gamma position (entries 8-10). Two 
cyclic dienoic acids were synthesized40-41 and while the cyclohexadienoic acid did not 
decarboxylate (entry 11), the vinylcyclopentenoic acid had a good yield of a complex 
tetraene (entry 12). 
Based on the information obtained during optimization and screening of 
compounds, two potential mechanisms are proposed (Scheme 4.3). Both options allow 
for the one (4.13) or two (4.5 and 4.6) component process to be used while also allowing 
for the reversible formation of linear ester 4.23. Pathway A involves a Morita-Baylis-
Hilmann type process. The role of water would be to hydrogen bond to the carboxylate to 
make the system more electrophilic (B). This would accelerate the addition of the 
phosphine to generate zwitterion C.42 Preliminary modeling for this ion indicates that 
both the electrophilic terminal vinyl group of the pentadienyl ligand and the nucleophilic 
α-carbon are in close proximity to one another. Formation of the carbon-carbon bond 
would then regenerate the Pd(0) catalyst and phosphonium carboxylate D. 
Decarboxylative elimination of the phosphine results in formation the 1,3,6,8-tetraene. It 
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is proposed for Pathway A that the dienoate is required so that the α-carbon is not 
blocked by the bulky phosphine group since it can add in a 1,6- or 1,4-manner, both  
reversibly. 
 
Scheme 4.3. Possible Mechanistic Pathways. 
Alternatively, Pathway B has the palladium catalyst coordinate to one of the 
alkenes of the dienoate instead of the carboxylate (E). It is proposed that a water cluster 
around the carboxylate would enable this process by hydrogen bonding to the 
carboxylate. The conversion of E to F would form the C-C bond by having the palladium 
catalyst convert from one type of η3-allyl and π-complex (E) to a different allyl/π-
complex (F). Finally, decarboxylative reduction of the palladium would release the 
product while regenerating the catalyst. Preliminary computational calculations using 
NEB43 support Pathway B and the HOMO of the transition state between E and F (Figure 
4.1) calculated using the Gaussian 09 implementation of DFT with a B3LYP functional, 
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6-31g* basis, and polarized continuum model of solvation for DCM, shows close 
proximity of two in-phase orbitals for the requisite C-C bond, whereas removal of any 
one of the alkenes from this structure would lead to anti-bonding relationships to bond to 
the alpha carbon. 
 
Figure 4.1. Calculated HOMO of Transition State between E and F. 
3. Conclusion 
In summary, we present information that is of value to advancing the area of 
metal-catalyzed decarboxylative coupling reactions, specifically those of pentadienyl 
dienoates that do not require an anion-stabilizing group, are run at ambient temperature, 
and can utilize the more accessible alcohol for a leaving group. This reaction was 
advanced to be possible in a two component fashion, allowing for the conversion of 
dienoic acids and pentadienyl alcohols into 1,3,6,8-tetraenes with the only stoichiometric 
byproducts being water and carbon dioxide. These reactions currently require a diene 
motif with each coupling partner, but the product maintains the independent reactivity 
opportunities of these isolated dienes as opposed to forming the fully conjugated, 1,3,5,7-
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tetraene. A variety of substrates were explored where each of the unique positions on the 
coupling partners was modified and two different mechanistic pathways are presented. A 
more in-depth mechanistic analysis to improve the yields and to explore other reactivity 
possibilities based on this process are currently being studied and will be published in due  
time. 
4. Experimental and Charecterization Data 
4.1 General Information 
All anhydrous reactions were performed in oven dried glassware under a nitrogen 
atmosphere. Unless otherwise noted, all solvents and reagents were obtained from 
commercial sources and used without further purification. NMR yields were obtained by 
using dimethyl terphthalate as an internal standard in a CDCl3 solution. Chromatographic 
purification was performed using silica gel (60 Å, 32-63 μm). NMR spectra were 
recorded in CDCl3 using a JEOL ECA 400 spectrometer (400 MHz for 
1H, 100 MHz for 
13C, and 376.5 MHz for 19F) and JEOL ECA spectrometer (500 MHz for 1H, 125 MHz 
for 13C, and 470 MHz for 19F). Coupling constants, J, are reported in hertz (Hz) and 
multiplicities are listed as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), 
doublet of doublets (dd), triplet of triplets (tt), multiplet (m), etc. High Resolution Mass 
Spectra were acquired on a Thermo Fisher Scientific LTQ Orbitrap XL MS system.  Low 
Resolution Mass Spectrometry was accomplished using Gas Chromatography on a  
Shimadzu GC2010-QP2010S instrument. 
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4.2 Kinetic Data for Different Phosphine Ligands 
 
To a prepared solution of Pd2dba3•CHCl3 (5 mol %) and designated ligand (see 
above and Chart; 20 mol %) in CDCl3 (0.1 M) was added pentadienyl dienoate 4.9 (20 
mg, 0.072 mmol) at ambient temperature. 1H NMR spectra were obtained upon 
dissolution of the reagents and subsequent 1H NMR spectra were obtained every 90 
minutes. The formation of the product 4.10 was monitored and plotted versus time in 
(Figure 4.2). 
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Figure 4.2. Formation of Product 4.10 Using Different Phosphine Ligands. 
4.3 Experimental Procedures and Characterization of Pentadienyl Dienoates 
 
Penta-1,4-dien-3-yl (2E,4E)-hexa-2,4-dienoate, 4.13 
To an ice-cooled solution of DCC (0.83 g, 4.0 mmol) in THF (15 mL) were 
sequentially added sorbic acid (0.50 g, 2.8 mmol), 1,4-pentadien-3-ol 4.6e (0.34 mL, 3.4 
mmol) and DMAP (70 mg, 0.57 mmol). The reaction was allowed to warm to room 
temperature for 18 hours before it was filtered through Celite® and washed with hexane. 
The filtrate was concentrated and purified via silica gel chromatography (95:5, 
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hexanes/EtOAc) to yield ester 4.13 (0.42 g, 82%) as a colorless oil. Rf = 0.78 (88:12, 
hexanes/EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 7.31 – 7.26 (m, 1H), 6.23 – 6.11 (m, 1H), 5.91 – 5.83 (m, 
3H), 5.80 – 5.77 (m, 2H), 5.30 (dt, Jd = 17.0 Hz, Jt = 1.5 Hz, 2H), 5.22 (dt, Jd = 10.0 Hz, 
Jt = 1.0 Hz, 2H), 1.86 (d, J = 6.0 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 166.3, 145.5, 139.7, 135.3 (2C), 129.8, 118.9, 117.4 
(2C), 74.8, 18.8 ppm.  
HRMS (APCI): calcd. for [C11H14O2+H]
+: 179.1067, found: 179.1066.  
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4.4 Experimental Procedures and Characterization of Dienoic Acids  
 
(E)-ethyl 4-methylpenta-2,4-dienoate, 4.S3 
Following a previously reported procedure, ester 4.S3 was synthesized as a light 
yellow oil, (1.2 g, 70%). Rf = 0.40 (95:5, hexanes/EtOAc).
 1H and 13C NMR are 
consistent with literature reports.44 
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1
H NMR (500 MHz, CDCl3) δ 7.35 (d, J = 16.0 Hz, 1H), 5.86 (d, J = 16.0 Hz, 1H), 5.36 
– 5.32 (m, 2H), 4.21 (q, J = 7.2 Hz, 2H), 1.88 (dd, J = 1.4, 0.8 Hz, 3H), 1.30 (t, J = 7.1  
Hz, 3H) ppm. 
 
 
(E)-ethyl 4-methylpenta-2,4-dienoic acid, 4.5d 
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Following a previously reported procedure, acid 4.5d was synthesized as an off-
white solid, (71 mg, 90%), Rf = 0.55 (50:50, hexanes/EtOAc, large streak).
 1H and 13C 
NMR are consistent with literature reports.44  
1
H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 15.7 Hz, 1H), 5.88 (d, J = 15.7 Hz, 1H), 5.41  
(s, 1H), 5.40 (s, 1H), 1.91 (d, J = 1.0 Hz, 3H) ppm. 
 
 
(E)-4-(p-tolyl)penta-2,4-dienoic acid, 4.5e 
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To a solution of trans-3-(4-methylbenzoyl)acrylic acid 4.S4 (1.0 g, 5.2 mmol) and 
methyltriphenylphosphonium bromide (2.8 g, 7.9 mmol) at -78 °C in THF (70 mL) was 
added dropwise a solution of potassium t-butoxide (1.1 g, 10 mmol) in THF (12 mL). The 
reaction mixture was allowed to warm gradually to room temperature for 2.5 hours and 
turned from yellow to dark orange. The mixture was quenched with water at 0 °C, 
acidified with 10% aqueous HCl to a pH ~ 3 and extracted 3x with EtOAc. The combined 
organic layers were dried using Na2SO4 and concentrated. Purification via silica gel 
chromatography (95:5, hexanes/EtOAc) yielded acid 4.5e (450 mg, 50%) as a yellow oil. 
Rf = 0.79 (95:5, hexanes/EtOAc). This compound was found to be unstable at room 
temperature for several hours and it was taken directly to the next reaction. Due to the 
instability, HRMS data was not obtained and the NMR spectra contained moderate 
solvent impurities. 
1
H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 15.9 Hz, 1H), 7.18 (s, 4H), 5.86 (d, J = 15.8 
Hz, 1H), 5.64 (s, 1H), 5.54 (s, 1H), 2.35 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 172.4, 148.3, 146.2, 138.0, 135.4, 129.2 (2C), 128.2 
(2C), 124.9, 120.7, 21.3 ppm. 
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Methyl 2-((methylsulfonyl)oxy)cyclopent-1-enecarboxylate, 4.S6 
See Chapter III-section 4.3, p.112 compound 3.26 for experimental details. 
 
Methyl 2-vinylcyclopent-1-ene-1-carboxylate, 4.S7 
See Chapter III-section 4.3, page 113 compound 3.27 for experimental details. 
171 
 
 
2-Ethenyl-1-cyclopentenecarboxylic Acid, 4.5g 
See Chapter III-section 4.3, page 114 compound 3.28 for experimental details. 
4.5 Experimental Procedures and Characterization of Pentadienyl Groups 
 
Penta-1,4-dien-3-yl acetate, 4.6a 
Following a previously reported procedure, acetate 4.6a was synthesized as a 
colorless liquid, (1.6 g, 64%). Rf = 0.44 (80:20, hexanes/EtOAc). 
1H and 13C NMR are 
consistent with literature reports.45 
1
H NMR (400 MHz, CDCl3) δ 5.83 (ddd, J = 17.0, 10.5, 6.0 Hz, 2H), 5.69 (tt, J = 6.0, 
1.2 Hz, 1H), 5.29 (dt, Jd = 17.1 Hz, Jt = 1.1 Hz, 2H), 5.22 (dt, Jd = 10.5 Hz, Jt = 1.2 Hz, 
2H), 2.09 (s, 3H) ppm. 
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Methyl penta-1,4-dien-3-yl carbonate, 4.6b 
Following a previously reported procedure, carbonate 4.6b was synthesized as a 
yellow liquid, (202 mg, 36%). Rf = 0.30 (80:20, hexanes/EtOAc). 
1H and 13C NMR are 
consistent with literature reports.46 
1
H NMR (500 MHz, CDCl3) δ 5.90 – 5.82 (m, 2H), 5.52 (tt, J = 6.3, 1.2 Hz, 1H), 5.35 
(dt, Jd = 17.2, Jt = 1.2 Hz, 2H), 5.27 (dt, Jd = 10.5, Jt = 1.2 Hz, 2H), 3.79 (s, 3H) ppm. 
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Penta-1,4-dien-3-yl benzoate, 4.6c 
Benzoyl chloride 4.S9 (5.2 mL, 45 mmol), Et3N (6.3 mL, 45 mmol) and DMAP 
(183 mg, 1.5 mmol) were sequentially added slowly to a precooled solution of 1,4-
pentadien-3-ol 4.6e (1.5 mL, 15 mmol) in CH2Cl2 (33 mL) at 0 °C. After stirring for 18 
hours at room temperature, the reaction was quenched with saturated NH4Cl solution, 
washed with hexane and extracted with CH2Cl2. The organic layers were combined, dried 
using Na2SO4 and concentrated. Purification via silica gel chromatography (90:10, 
hexanes/EtOAc) yielded benzoate 4.6c (1.4 g, 48%) as a colorless liquid. Rf = 0.18 
(90:10, hexanes/EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 8.10 – 8.08 (m, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.45 (t, J = 
7.7 Hz, 2H), 6.01 – 5.92 (m, 3H), 5.43 – 5.38 (m, 2H), 5.29 (d, J = 9.6 Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 165.6, 135.1 (2C), 133.1, 130.4, 129.8 (2C), 128.5 (2C), 
117.7 (2C), 75.6 ppm. 
HRMS (APPI) calcd. for [C12H12O2+H]
+: 189.0910, found: 189.0909. 
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Penta-1,4-dien-3-yl 4-(trifluoromethyl)benzoate, 4.6d 
To a solution of 1,4-pentadien-3-ol 4.6e (0.25 mL, 2.6 mmol) in CH2Cl2 (26 mL) 
precooled to 0 °C, were sequentially added 4-(trifluoromethyl)benzoyl chloride 4.S10 
(0.4 mL, 2.6 mmol), Et3N (1.1 mL, 7.7 mmol) and DMAP (31 mg, 0.25 mmol). After 
stirring for 18 hours at room temperature, the reaction was quenched with saturated 
NH4Cl solution, washed with hexane and extracted with CH2Cl2. The organic layers were 
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combined and dried using Na2SO4 and concentrated. Purification via silica gel 
chromatography (90:10, hexanes/EtOAc) yielded benzoate 4.6d (529 mg, 83%) as a faint 
yellow liquid. Rf = 0.82 (80:20, hexanes/EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 8.2 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 6.01 – 
5.92 (m, 3H), 5.44 – 5.38 (m, 2H), 5.31 (d, J = 9.6 Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 164.4, 134.8 (2C), 134.5 (q, JC-F = 45 Hz, 1C), 133.7, 
130.2 (2C), 125.5 (q, JC-F = 4.0 Hz, 2C), 123.7 (q, JC-F = 272 Hz, 1C), 118.1 (2C), 76.3 
ppm. 
19
F NMR (376.5 MHz, CDCl3) δ -63.00 (s, 3F) ppm. 
HRMS (APPI) calcd. for [ C13H11O2F3]
+: 256.0711, found: 256.0706. 
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(E)-5-bromo-1,3-diene, 4.7a 
To a stirred solution of 1,4-pentadien-3-ol 4.6e (0.50 mL, 5.1 mmol) in pentane 
(0.4 mL) at 0 °C, was added HBr (0.5 mL, 9.2 mmol, 48%) dropwise. After stirring for 4 
hours the reaction mixture was diluted with diethyl ether, quenched with a saturated, 
aqueous sodium bicarbonate solution, extracted with diethyl ether and dried over Na2SO4. 
The solution was concentrated and purified via silica gel chromatography (pentane) to 
give 4.7a (200 mg, 28%) as a colorless liquid. Rf = 0.90 (80:20, hexanes/EtOAc).
 The 
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product is a mixture of two diastereomers in a 10:1 ratio. Only the major, E diastereomer, 
was fully characterized. 1H and 13C NMR are consistent with literature reports.47 
1
H NMR (400 MHz, CDCl3) δ 6.38 – 6.26 (m, 2H), 5.89 (dt, Jd = 13.6, Jt = 7.8 Hz, 1H), 
5.30 – 5.26 (m, 1H), 5.17 (dd, J = 9.3, 1.7 Hz, 1H), 4.03 (d, J = 8.0 Hz, 2H) ppm. 
 
 
(1E)-1-phenylpenta-1,4-dien-3-ol, 4.6f 
Vinyl magnesium bromide (0.7 M in THF, 13 mL, 9.1 mmol) was added dropwise 
to a precooled solution of trans-cinnamaldehyde 4.S11 (0.95 ml, 7.6 mmol) in THF (10 
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mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred 
for 4 hours before it was  quenched with saturated NH4Cl solution and extracted with 
ethyl acetate. The organic layers were combined, dried using MgSO4, and filtered. The 
solution was concentrated and purified via silica gel chromatography (80:20, 
hexanes/EtOAc) which yielded alcohol 4.6f (938 mg, 86%) as a yellow oil. Rf = 0.26 
(80:20, hexanes/EtOAc). 1H and 13C NMR are consistent with literature reports.48 
1
H NMR (400 MHz, CDCl3) δ 7.41 – 7.39 (m, 2H), 7.34 – 7.30 (m, 2H), 7.25 (t, J = 7.0 
Hz, 1H), 6.62 (d, J = 16.0 Hz, 1H), 6.24 (dd, J = 16.0, 6.4 Hz, 1H), 5.98 (ddd, J = 16.8, 
10.5, 5.9 Hz, 1H), 5.35 (dt, Jd = 17.5, Jt = 1.4 Hz, 1H), 5.21 (dt, Jd = 10.3, Jt = 1.1 Hz, 
1H), 4.82 (t, J = 6.4 Hz, 1H), 1.75 (bs, 1H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 139.3, 136.7, 130.9, 130.4, 128.7 (2C), 127.9, 126.7 
(2C), 115.6, 73.9 ppm. 
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(E)-1-phenylpenta-1,4-dien-3-yl acetate, 4.6g 
Acetic anhydride (0.45 mL, 4.3 mmol) was added dropwise to a solution of 
DMAP (0.95 g, 0.78 mmol) and (E)-1-phenylpenta-1,4-dien-3-ol 4.6f (0.55 g, 3.5 mmol) 
in CH2Cl2 (7.1 mL) at 0 ºC. The reaction mixture was allowed to warm to room 
temperature and stirred for 24 hours before it was concentrated under reduced pressure 
and purified via silica gel chromatography (97:3, hexanes/EtOAc) to yield acetate 4.6g 
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(168 mg, 53%) as a yellow oil. Rf = 0.56 (97:3, hexanes/EtOAc).
 1H and 13C NMR are 
consistent with literature reports.49 
1
H NMR (400 MHz, CDCl3) δ 7.32 – 7.21 (m, 3H), 7.19 – 7.15 (m, 2H), 6.56 (d, J = 
16.0 Hz, 1H), 6.25 – 6.12 (m, 1H), 6.10 (dd, J = 16.0, 6.8 Hz, 1H), 5.89 – 5.74 (m, 1H),  
5.30 – 5.26 (m, 1H), 5.20 – 5.17 (m, 1H), 2.03 (s, 3H) ppm. 
 
 
Methyl cyclohexa-1,3-diene-1-carboxylate, 4.S13 
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Following a previously reported procedure, ester 4.S1341 was synthesized as a 
colorless oil, (350 mg, 30%). Rf = 0.38 (75:25, hexanes/EtOAc). 
1H and 13C NMR are 
consistent with literature reports.41 This compound was prone to air oxidation to methyl 
benzoate so it was moved forward synthetically prior to complete removal of solvent. 
1
H NMR (400 MHz, CDCl3) δ 7.00 – 6.96 (m, 1H), 6.13 (dt, Jd = 8.6, Jt = 4.3 Hz, 1H), 
6.05 (ddt, Jd = 9.5, 5.5, Jt = 1.8 Hz, 1H), 3.74 (s, 3H), 2.48 – 2.37 (m, 2H), 2.29 – 2.21  
(m, 2H) ppm. 
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1,3-cyclohexadiene-1-methanol, 4.S14 
DIBAL-H in toluene (1.2 M, 4.1 mL, 5.0 mmol) was added to ester 4.S13 (350 
mg, 2.5 mmol) in THF (10 mL) at -78 ºC. The reaction was allowed to warm to room 
temperature and stirred overnight. The reaction mixture was filtered through Celite®, 
acidified with 10% aqueous HCl, extracted with diethyl ether, and dried using Na2SO4. 
The solution was concentrated and purified via silica gel chromatography (80:20, 
hexanes/EtOAc) to give (274 mg, 99%) of alcohol 4.S14. Rf = 0.19 (80:20, 
hexanes/EtOAc). 1H and 13C NMR are consistent with literature reports.50 This 
compound was prone to air oxidation to benzyl alcohol so it was moved forward 
synthetically prior to complete removal of solvent. 
1
H NMR (400 MHz, CDCl3) δ 5.94 – 5.87 (m, 2H), 5.77 (dt, Jd = 9.0, Jt = 4.0 Hz, 1H), 
4.11 (s, 2H), 3.4 (s, OH), 2.26 – 2.13 (m, 4H) ppm. 
 
188 
 
 
 
Cyclohexa-1,3-dien-1-ylmethyl acetate, 4.7e 
To a solution of alcohol 4.S14 (274 mg, 2.5 mmol) in CH2Cl2 (25 mL) was added 
acetic anhydride (0.25 mL, 2.5 mmol) and DMAP (61 mg, 0.5 mmol) at 0 °C. After 
stirring for 18 hours at room temperature, the reaction was diluted with CH2Cl2 and 
washed with water. The aqueous layer was back extracted with CH2Cl2, and the 
combined organic layers were dried using Na2SO4 and concentrated to give acetate 4.7e 
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(171 mg, 45%) as a yellow liquid. Rf = 0.65 (90:10, hexanes/EtOAc). Due to the 
instability, HRMS data was not obtained. 
1
H NMR (400 MHz, CDCl3) δ 5.92 – 5.89 (m, 2H), 5.81 – 5.77(m, 1H), 4.55 (s, 2H), 
2.25 – 2.10 (m, 4H), 2.09 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 171.1, 132.8, 126.6, 123.9, 122.2, 67.7, 23.6, 22.6, 21.1  
ppm. 
 
190 
 
 
  
(2-vinylcyclopent-1-en-1-yl)methanol, 4.S15 
DIBAL-H in toluene (1.2 M, 1.0 mL, 1.2 mmol) was added to ester 4.S7 (88 mg, 
0.58 mmol) in THF (5.8 mL) at -78 ºC. The reaction was warmed to room temperature. 
After stirring for 4 hours the reaction mixture was quenched first with Na2SO4•10H2O 
until bubbling ceased and then with saturated NH4Cl solution, extracted with diethyl 
ether, and dried using Na2SO4. The solution was concentrated and purified via silica gel 
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chromatography (80:20, pentane/diethyl ether) to give alcohol 4.S15 (53 mg, 75%) as a 
yellow oil. Rf = 0.31 (80:20, hexanes/EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 6.70 (dd, J = 17.2, 10.7 Hz, 1H), 5.14 – 5.10 (m, 2H), 
4.31 (s, 2H), 2.56 (t, J = 7.4 Hz, 2H), 2.52 (t, J = 7.6 Hz, 2H), 1.87 (quint, J = 7.5 Hz, 
2H) ppm. 
13
C NMR (125 MHz, CDCl3) δ 140.3, 137.5, 130.3, 115.0, 58.8, 35.2, 32.8, 21.5 ppm. 
HRMS (ESI) calcd. for [C8H12O+H]
+: 125.0966, found: 125.0961. 
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(2-vinylcyclopent-1-en-1-yl)methyl acetate, 4.7d 
To a solution of alcohol 4.S15 (20 mg, 0.16 mmol) and triethylamine (45µL, 0.32 
mmol) in CH2Cl2 (1.6 mL) was added acetic anhydride (19 µL, 0.19 mmol) and DMAP 
(2.0 mg, 0.016 mmol) at 0 °C. After stirring for an hour at room temperature, the reaction 
was diluted with diethyl ether and washed with water. The aqueous layer was back 
extracted with diethyl ether, and the combined organic layers dried using Na2SO4 and 
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concentrated. Purification via silica gel chromatography (95:5, pentane/diethyl ether) 
yielded acetate 4.7d (15 mg, 56%) as a yellow oil. Rf = 0.76 (80:20, hexanes/EtOAc). 
1
H NMR (500 MHz, CDCl3) δ 6.70 (dd, J = 16.8, 11.1 Hz, 1H), 5.17 (d, J = 16.7 Hz, 
1H), 5.16 (d, 11.0 Hz, 1H), 4.76 (s, 2H), 2.55 – 2.50 (m, 4H), 2.06 (s, 3H), 1.88 (quint, J 
= 7.6 Hz, 2H) ppm. 
13
C NMR (125 MHz, CDCl3) δ 171.2, 139.8, 135.3, 130.0, 115.8, 60.4, 35.5, 32.7, 21.4, 
21.0 ppm. 
GC-LR-MS (EI 70 eV) m/z (%) calcd. for [C10H14O2]
+: 166, found: 166. 
Attempts to obtain HRMS data using ESI and API were unsuccessful.  
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4.6 Experimental Procedures for Single Component Decarboxylative Coupling 
 
(6E/Z,8E)-methyl 6-allylideneundeca-8,10-dienoate, 4.10   
See Chapter III-section 3.2.1, page 79 compound 3.9 for experimental details, 
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(6E)-4-ethylnona-1,3,6,8-tetraene, 4.12 
Dienoate 4.11 (40 mg, 0.17 mmol)39 was added to a small vial with CH2Cl2 (2 
mL) after which tetrakis-(triphenylphosphine) palladium (19.7 mg, 0.017 mmol) was 
added. The vial was sealed and purged with N2. When initially prepared, the solution was 
a dark orange color, but after 24 hours, it was a light yellow color.  At this time, the 
reaction was concentrated and purified via silica gel chromatography (hexanes) to yield 
ethyl tetraene 4.12. The yield was inconsistent due to the extreme volatility of the product 
which made removing solvent difficult.39 
Diastereomer A: 
1
H NMR (500 MHz, CDCl3) δ 7.18 (d, J = 11.5 Hz, 1H), 6.68 (ddd, J = 10.3, 11.3, 16.8 
Hz, 1H), 5.89 (ddd, J = 5.8, 10.3, 16.6 Hz, 2H), 5.84 – 5.78 (m, 1H), 5.59 (dd, J = 1.1, 
16.6 Hz, 1H), 5.47 (dd, J = 1.1, 10.3 Hz, 1H), 5.37 – 5.31 (m, 2H), 5.27 – 5.23 (m, 2H), 
2.46 (q, J = 7.4 Hz, 2H), 1.06 (t, J = 7.4 Hz, 3H) ppm. 
Diastereomer B: 
1
H NMR (500 MHz, CDCl3) δ 7.31 – 7.22 (m, 1H), 6.38 (d, J = 11.5 Hz, 1H), 5.89 (ddd, 
J = 5.8, 10.3, 16.6 Hz, 2H), 5.84 – 5.78 (m, 1H), 5.40 (dd, J = 1.7, 17.1 Hz, 1H), 5.37 – 
5.31 (m, 3H), 5.27 – 5.23 (m, 2H), 2.38 (q, J = 7.4 Hz, 2H), 1.09 (t, J = 7.5 Hz, 3H) ppm. 
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(6E,8E)-deca-1,3,6,8-tetraene, 4.8a 
To a microwave vial with dienoate 4.13 (11 mg, 0.063 mmol) and water (1.25 µL, 
0.07 mmol) in CDCl3 (1.5 mL) was added tetrakis-(triphenylphosphine) palladium (7.3 
mg, 0.0063 mmol) and the vial was sealed and purged with N2. The mixture was stirred at 
room temperature for 24 hours and then transferred to a vial containing 
dimethylterphthalate (2.6 mg, internal standard). Quantitative 1H NMR analysis of this 
mixture shows the formation of tetraene 4.8a (5%) in addition to the rearranged ester 
4.20. The spectral data for (6E,8E)-deca-1,3,6,8-tetraene, 4.8a is provided below for the  
two component reaction. 
4.7 Experimental Procedures for Two Component Decarboxylative Coupling 
General Procedure: A microwave vial with dienoic acid 4.5 (1.0 eq), pentadienyl 
substrate 4.6 (1.2 eq) and water (1.1 eq) in CDCl3 (0.1 M) was capped with a septum, and 
purged with N2. Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (5 mol %) 
and PPh3 (20%) were dissolved in  CDCl3 (0.1 mL) and added to the mixture. The 
mixture was left at room temperature under a balloon of N2 for 48 hours. The solution 
was concentrated and purified via silica gel chromatography using pentane. 
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(6E,8E)-deca-1,3,6,8-tetraene, 4.8a 
Following the general procedure, tetraene 4.8a was synthesized as a colorless 
solution in CDCl3 (40% 
1H NMR yield). Rf (mixture of diastereomers) = 0.78 (hexanes). 
The product is a mixture of two diastereomers in a 10:1 ratio. Only the major, all-E 
diastereomer, was fully characterized. 
1
H NMR (500 MHz, CDCl3) δ 6.63 (dddd, J = 16.9, 11.2, 10.2, 1.1 Hz, 1H), 6.07 – 5.99 
(m, 3H), 5.64 – 5.58 (m, 1H), 5.57 – 5.50 (m, 1H), 5.47 – 5.42 (m, 1H), 5.23 (dd, J = 
16.8, 2.0 Hz, 1H), 5.12 (d, J = 10.2 Hz, 1H), 3.07 (t, J = 7.5 Hz, CH2 minor isomer), 2.95 
(t, J = 7.1 Hz, 2H), 1.73 (d, J = 6.0 Hz, 3H) ppm. 
13
C NMR (125 MHz, CDCl3) δ 132.1, 131.4, 131.1, 129.9, 129.8, 129.1, 127.8, 117.7, 
30.8, 18.2 ppm. 
GC-LR-MS (EI 70 eV) m/z (%) calcd. for C10H14: 134, found: 134. 
Attempts to obtain HRMS data using ESI and API were unsuccessful. 
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5-methyldeca-1,3,6,8-tetraene, 4.8b 
Following the general procedure, tetraene 4.8b was synthesized as a colorless oil 
(3.4 mg, 8% yield). Rf = 0.63 (hexanes). The product is a mixture of two isomers 
4.8b/4.8c in a 6:1 ratio. Only the major isomer 4.8b was fully characterized. 
1
H NMR (400 MHz, CDCl3) δ 6.68 – 6.58 (m, 1H), 6.06 – 5.92 (m, 3H), 5.68 – 5.55 (m, 
1H), 5.49 (dd, J = 14.3, 6.3 Hz, 1H), 5.27 (t, J = 10 Hz, 1H), 5.19 (dd, J = 16.8, 1.9 Hz, 
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1H), 5.10 (td, Jd = 9.9, Jt = 2.0 Hz, 1H), 3.35 (dq, Jq = 16.0, Jd = 6.8, 1H), 2.91 (t, J = 6.7 
Hz, CH2 minor isomer 4.8c), 1.73 (d, J = 6.6 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3) δ 136.3, 135.4, 132.3, 131.6, 128.8, 128.1, 127.9, 117.6, 
34.9, 21.0, 18.2 ppm. 
GC-LR-MS (EI 70 eV) m/z (%) calcd. for C11H16: 148, found: 148. 
Attempts to obtain HRMS data using ESI and API were unsuccessful. 
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(deca-1,3,6,8-tetraen-5-yl)benzene, 4.8d 
Following the general procedure, tetraene 4.8d was synthesized as a colorless oil, 
(6.3 mg, 17% isolated yield). Rf = 0.37 (hexanes). The product is a mixture of two 
isomers 4.8d/4.8e in a 2:1 ratio. Only the major isomer 4.8d was fully characterized. 
1
H NMR (400 MHz, CDCl3) δ 7.45 – 7.38 (m, 1H), 7.35 – 7.27 (m, 2H), 7.25 – 7.15 (m, 
2H), 6.73 (dt, Jd = 16.9, Jt = 10.6 Hz, 1H), 6.12 – 6.04 (m, 3H), 5.74 – 5.49 (m, 3H), 5.27 
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(dd, J = 16.9, 9.2 Hz, 1H), 5.17 (dd, J = 10.4, 1.9 Hz, 1H), 4.54 (dd, J = 9.9, 6.5 Hz, 1H, 
CH benzylic major isomer 4.8d), 3.05 (t, J = 7.2 Hz, 2H, CH2 minor isomer 4.8e), 1.74 
(d, J = 6.1 Hz, 3H, major isomer 4.8d) 1.73 (d, J = 6.1 Hz, 3H, CH3 minor isomer 4.8e) 
ppm. 
13
C NMR (100 MHz, CDCl3) δ 133.2, 132.7, 132.0, 131.3, 131.0, 129.2, 128.8, 128.7, 
128.6 (2C), 127.7 (2C), 126.5, 118.7, 46.2, 18.2 ppm. 
GC-LR-MS (EI 70 eV) m/z (%) calcd. for C16H18: 210, found: 210. 
Attempts to obtain HRMS data using ESI and API were unsuccessful.  
 
205 
 
 
 
3-methylene-6-((1E,3E)-penta-1,3-dien-1-yl)cyclohex-1-ene, 4.8f 
Following the general procedure, tetraene 4.8f was synthesized as a light yellow 
oil, (3.5 mg, 16%). Rf = 0.96 (90:10, hexanes/EtOAc). 
1
H NMR (400 MHz, CDCl3) δ 6.17 (dd, J = 10.0, 2.2 Hz, 1H), 6.05 – 5.99 (m, 2H), 5.69 
(dd, J = 9.7, 3.7 Hz, 1H), 5.65 – 5.60 (m, 1H), 5.55 – 5.49 (m, 1H), 4.80 (s, 1H), 4.77 (s, 
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1H), 2.94 – 2.88 (m, 1H), 2.44 – 2.35 (m, 1H), 2.34 – 2.25 (m, 1H), 1.87 (ddt, Jt = 12.6, 
Jd = 7.5, Jd = 4.5 Hz, 1H), 1.74 (d, J = 6.5 Hz, 3H), 1.56 – 1.47 (m, 1H) ppm. 
13
C NMR (125 MHz, CDCl3) δ 143.0, 134.3, 132.7, 131.5, 130.3, 129.6, 128.1, 111.2, 
38.5, 29.5, 28.8, 18.3 ppm. 
HRMS (APPI) calcd. for [C12H16]
+: 160.1246, found: 160.1245. 
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1-(hexa-2,4-dien-1-yl)-2-vinylcyclopent-1-ene, 4.8g 
Following the general procedure, tetraene 4.8g was synthesized as a colorless oil, 
(2.0 mg, 18%). Rf = 0.96 (90:10, hexanes/EtOAc). The product is a mixture of two 
diastereomers in a 2:1 ratio. Only the major diastereomer was fully characterized. 
1
H NMR (500 MHz, CDCl3) δ 6.67 (dd, J = 16.8, 11.0 Hz, 1H), 6.06 – 5.95 (m, 2H), 
5.63 – 5.55 (m, 1H), 5.53 – 5.45 (m, 1H), 5.09 – 5.02 (m, 2H), 2.96 (d, J = 6.9 Hz, 2H), 
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2.50 – 2.47 (m, 2H), 2.42 – 2.39 (m, 2H), 1.85 – 1.79 (m, 2H), 1.72 (d, J = 6.5 Hz, 3H) 
ppm. 
13
C NMR (125 MHz, CDCl3) δ 140.7, 131.5, 131.4, 131.0, 130.9, 128.7, 127.7, 113.3, 
37.1, 32.6, 31.8, 21.5, 18.2 ppm. 
HRMS (APPI) calcd. for [C13H18+H]
+: 175.1487, found: 175.1480. 
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Nona-1,3,6,8-tetraene, 4.8h/4.8i/4.8j 
Following the general procedure, tetraenes 4.8h/4.8i/4.8j were synthesized as a 
colorless solution in CDCl3 (14% 
1H NMR yield). Rf = 0.73 (hexanes).  
Mixture of three inseparable diastereomers (E/E, E/Z, Z/Z)  
1
H NMR (400 MHz, CDCl3) δ 6.71 – 6.58 (m, 1H), 6.38 – 6.27 (m, 1H), 6.13 – 6.00 (m, 
2H), 5.70 (dq, Jd = 15.3 Hz, Jq = 6.4 Hz, 1H), 5.50 – 5.40 (m, 1H), 5.23 (dd, J = 16.9, 1.6 
Hz, 1H), 5.15 – 5.1 (m, 2H), 4.99 (dd, J = 10.0, 3.3 Hz, 1H), 3.09 (t, J = 7.6 Hz, 0.53H 
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diastereomer 4.8h), 2.99 (t, J = 7.1 Hz, 0.99H diastereomer 4.8i), 2.99 (t, J = 6.7 Hz, 
0.60H diastereomer 4.8j) ppm. 
13
C NMR (100 MHz, CDCl3) δ 137.0, 132.5, 132.3, 132.1, 132.0, 131.9, 131.6, 130.2, 
129.8, 129.8, 129.3, 117.8, 115.7, 115.6, 35.4, 30.7, 26.6 ppm.  
GC-LR-MS (EI 70 eV) m/z (%) calcd. for C9H12: 120, found: 120. 
Attempts to obtain HRMS data using ESI and API were unsuccessful.  
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((1E,3E,6E)-nona-1,3,6,8-tetraen-1-yl)benzene, 4.8k 
Following the general procedure, tetraene 4.8k was synthesized as a yellow oil 
(8.2 mg, 24% yield). Rf = 0.62 (hexanes).  
1
H NMR (400 MHz, CDCl3) δ 7.37 – 7.35 (m, 2H), 7.29 (dt, Jd = 8.6 Hz, Jt = 6.8 Hz, 
2H), 7.19 (tt, J = 6.4, 1.2 Hz, 1H), 6.75 (dd, J = 15.6, 10.5 Hz, 1H), 6.64 (dtd, Jd = 16.9, 
1.0 Hz, Jt = 10.6 Hz, 1H), 6.45 (d, J = 12.0 Hz, 1H), 6.23 (ddt, Jd = 14.0, 10.4 Hz, Jt = 
1.7, 1H), 6.09 (t, J = 11 Hz, 1H), 5.80 (dt, Jd = 15.0 Hz, Jt = 6.6 Hz 1H), 5.49 (dt, Jd = 
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10.7 Hz, Jt = 7.9 Hz, 1H), 5.23 (dd, J = 16.9, 1.6 Hz, 1H), 5.14 (td, Jd = 10.4, Jt = 1.9 Hz, 
1H), 3.04 (t, J = 7.1 Hz, 2H) ppm.  
13
C NMR (100 MHz, CDCl3) δ 137.6, 132.7, 132.0, 131.3, 130.8, 130.3, 129.3, 129.1, 
128.6 (2C), 127.3, 126.2 (2C), 117.9, 31.1 ppm. 
HRMS (APPI) calcd. for [C15H16 + H]
+: 197.1330, found: 197.1323. 
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(3E,6E)-2-methylnona-1,3,6,8-tetraene, 4.8l 
Following the general procedure, tetraene 4.8l was synthesized as a colorless 
liquid (36% 1H NMR yield). Rf = 0.69 (hexanes). The product is a mixture of two 
diastereomers in a 4:1 ratio.  
Mixture of two inseparable diastereomers:  
1
H NMR (500 MHz, CDCl3) δ 6.65 (dddd, J = 16.8, 11.2, 10.2, 1.1 Hz, 1H, minor 
isomer), 6.34 (dtd, Jd = 17.0, 0.7 Hz, Jt = 10.2 Hz, 1H, major isomer), 6.21 – 6.12 (m, 
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1H), 6.12 – 6.01 (m, 1H), 5.73 (dtd, Jd = 15.2, 0.7 Hz, Jt = 6.8 Hz, 1H), 5.68 – 5.58 (m, 
1H), 5.52 – 5.42 (m, 1H, minor isomer), 5.25 – 5.21 (m, 1H, minor isomer), 5.15 – 5.11 
(m, 1H), 5.00 (ddd, J = 10.3, 1.6, 0.9 Hz, 1H), 4.90 – 4.88 (m, 2H), 3.01 (t, J = 7.1 Hz, 
2H, CH2 minor isomer), 2.90 (t, J = 6.7 Hz, 2H, CH2 major isomer), 1.84 (t, J = 1.0 Hz, 
3H, CH3 major isomer), 1.83 (t, J = 1.0 Hz, 1H, CH3 minor isomer) ppm. 
13
C NMR (125 MHz, CDCl3) δ 142.1, 137.1, 134.0, 133.6, 132.8, 132.1, 131.9, 130.1, 
129.7, 128.2, 128.0, 115.6, 115.2, 115.1, 35.7, 29.8, 18.8 ppm. 
GC-LR-MS (EI 70 eV) m/z (%) calcd. for C10H14: 134, found: 134. 
Attempts to obtain HRMS data using ESI and API were unsuccessful. 
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(E,Z)-1(penta-2,4-dien-1-yl)-2-vinylcyclopent-1-ene, 4.8m 
 See Chapter III-section 4.3, page 116 compound 3.29 for experimental details, 
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CHAPTER V 
CONCLUSION 
Isocarbacyclin and its analogues play an important role in treating neuronal 
damage following an ischemic stroke which makes the synthesis of new analogues 
important. The enantioselective total synthesis of isocarbacyclin is described herein using 
only 9 steps from inexpensive, commercially available materials. Three metal-catalyzed 
reactions including Pd
0
-catalyzed decarboxylation, Rh
I
-catalyzed cycloaddition and Ru
II
-
catalyzed cross metathesis were utilized in this synthesis. Other analogues were 
synthesized by attaching different ω-sidechains in a late-stage to shorten the synthesis to 
7-8 steps. Isocarbacyclin and its analogues were sent to a research lab that studies 
ischemic stroke to test their neuroprotective activity. 
Another generation of isocarbacyclin analogues was developed to increase the 
yield of the cycloaddition step compared to isocarbacyclin synthesis. A model system 
worked successfully for this generation where the three metal-catalyzed reactions that 
were used in the synthesis of isocarbacyclin were tested. However, efforts toward the 
cycloaddition step resulted in a different type of reaction. For future analogues of this 
type, the carboxyl group will be revealed at a late stage in the synthesis. 
The decarboxylation coupling reaction of pentadienyl dienoate that was 
discovered in the synthesis of isocarbacyclin and its analogues was studied in more detail. 
Different conditions were screened to optimize the reaction. It was found that both 
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pentadienyl and dienoate groups are required for the decarboxylative coupling reaction. 
The decarboxylative coupling was found to work at ambient temperature and without the 
need of an anion-stabilizing group. Other different conditions were screened to study the 
mechanism, which was studied more in detail by computational studies. Having the 
reaction optimized, different 1,3,6,8-tetraenes were synthesized using this type of 
reaction. 
 
